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Streptomyces genomes encode numerous gene clusters able to synthesize secondary 
metabolites with potential pharmaceutical applications. However, a great number of these 
genes remain unexpressed under standard laboratory growth conditions, therefore hiding a 
rich reservoir of natural products in their encoded metabolic pathways. In this work, we 
applied two strategies to induce the expression of silent gene clusters from Streptomyces 
albus subsp. chlorinus: heterologous expression and in situ ribosome engineering. 
In the first approach, a cryptic gene cluster encoded by S. albus subsp. chlorinus genome 
was heterologously expressed in the chassis strain Streptomyces albus Del14. The resulting 
strain produced the previously known antibiotic nybomycin, which is potently active against 
quinolone-resistant Staphylococcus aureus. Expression of the nybomycin cluster in S. albus 
Del14 also resulted in the biosynthesis of the novel compound benzanthric acid, which might 
be the product of interaction between the nybomycin pathway and the host´s metabolism. 
In the second approach, we selected a highly streptomycin-resistant mutant derived from 
S. albus subsp. chlorinus. This strain exhibited enhanced expression of a type II PKS gene 
cluster compared to the wild type strain, leading to overproduction of the novel compound 
fredericamycin C2. A point mutation leading to lack of RsmG protein is likely to be 





Das Chromosom von Streptomyceten enthält zahlreiche Gencluster, welche die Baupläne 
für die Synthese von Naturstoffen und potentiellen Therapeutika beinhalten. Dennoch kann 
unter Standard-Laborbedingungen oftmals nur eine unzureichende Expression dieser Gene 
erzielt werden. Eine bedeutende Anzahl von Naturstoffen bleibt somit unentdeckt. In dieser 
Arbeit haben wir zwei unterschiedliche Strategien angewandt, um die Expression von stillen 
Genclustern des Stammes Streptomyces albus subsp. chlorinus zu aktivieren: Heterologe 
Expression und in situ Ribosom-Engineering. 
Im ersten Ansatz wurde ein kryptisches Gencluster aus S. albus subsp. chlorinus im Wirt 
Streptomyces albus Del14 exprimiert. Die Mutante produzierte Nybomycin, ein bereits 
bekanntes Antibiotikum mit hoher Aktivität gegen Chinolon-resistenten Staphylococcus 
aureus.  Die Expression des Nybomycin-Genclusters in S. albus Del14 stimulierte außerdem 
die Synthese des neuen Naturstoffs Benzanthric Acid - einem Produkt aus der Interaktion 
des Nybomycin-Stoffwechsels mit dem Wirtsmetabolismus. 
Für den zweiten Ansatz wurde eine stark Streptomycin-resistente Mutante von S. albus 
subsp. chlorinus gewählt, die im Vergleich zum Wildtyp eine erhöhte Expression eines Type II 
PKS Genclusters aufwies. Dies führte zur Produktionssteigerung der neuen Substanz 
Fredericamycin C2. Ursächlich für diesen Phänotyp ist das Fehlen des RsmG-Proteins 
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1.1. Importance of natural products in the pharmaceutical industry 
Natural products (NPs) are substances derived from natural sources such as plants, 
animals, and microbes. It is estimated that about 25% of all known natural products –over 
one million– display biological activities [1] that make them applicable in different industrial 
fields: pharmacy, agriculture, food preservation, and cosmetics, among others. More 
specifically in the pharmaceutical industry, NPs have found multiple uses, e.g. antibacterial, 
antiviral and antitumor drugs, antiparasitics, immunosuppressants, and cholesterol-reducing 
agents. According to the US Food and Drug Administration (FDA), more than 50% of all the 
new drugs approved between 1981 and 2019 were of natural origin or NP-based 
compounds, indicating the significance of NPs in the current therapeutic scenario [2]. The 
major category of all approved substances is represented by the anti-infective agents, of 
which 78% are NPs or their derivatives, showing the value of natural compounds in human 
health. 
In the 1940s, the development of large scale production of penicillin from 
Penicillium fungi encouraged big pharmaceutical companies to focus their research on 
natural sources for the discovery of other antibiotics. Most of the antibiotic classes known 
up to date were discovered in the period between the 1940s and the 1970s, the “golden 
era” of antibiotics [3]. For instance, streptomycin and other aminoglycosides, a group of 
antibiotics potently active against Gram-negative bacteria, were first isolated by the 
Waksman group in the late 1940s [4]. Later on, other classes of antibiotics were 
characterised, such as penicillins, cephalosporins and tetracyclines [5-7]. Nevertheless, the 
high rate of bioactive microbial drugs discovery (200-300 per year in the late 1970s) 
drastically decreased in the last decades of the 20th century [1]. Some of the reasons for this 
decline were the high degree of rediscovery of known compounds, the difficulties in finding 
new potential producers due to extensive screening of terrestrial environments, and the 
small production yields [8]. Additionally, strict safety requirements, long duration time of 
clinical trials, short patent legitimacy periods and great market pressure to produce rapidly 
and profitably made NPs a less attractive source for drug development [9]. As a 
consequence, the pharmaceutical companies lost interest in NPs and redirected their drug 
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discovery programs towards the emerging high-throughput screening (HTS) of combinatorial 
synthetic compound libraries [10]. 
Despite the increasing interest in synthetic libraries, they present a series of 
disadvantages in relation to those based on NPs. First, the chemical diversity of synthetic 
libraries is limited by the oral bioavailability of the drugs, resulting in redundant collections 
of compounds that share similar structural cores [11]. In this regard, NPs and their 
derivatives offer a greater range of pharmacophores, more complex three-dimensional 
configurations, and higher number of stereocenters than purely synthetic molecules [12]. 
Second, despite the excellent toxicological and pharmacological properties of synthetic 
drugs, their range of targets is considerably narrower than that of NPs [13,14]. Third, they 
are generally inefficient in penetrating the complex cell wall of Gram-negative bacteria, in 
contrast to NP drugs and their analogues [15]. NPs have evolved for billion years to enter the 
cells and specifically bind proteins and other metabolites, becoming very efficient bioactive 
weapons of natural producers against their competitors [14]. Briefly, NPs still remain a highly 
valuable source of drug leads for the development of therapeutic agents that needs to be 
further explored. 
During the 1990s and early 2000s, the attempts of the pharmacy industry to develop new 
drugs based on combinatorial chemistry approaches were rather disappointing. HTS of 
synthetic libraries has an average hit rate of <0.001%, much lower than the 0.3% hit rate 
resulting from the screening of NPs [16]. As a consequence of the moderate success of the 
chemistry-based discovery methods, the overall number of new active drugs approved by 
the FDA per year has significantly decreased between the 1990s and the 2000s [2]. This has 
especially affected the field of antibiotics. According to the World Health Organisation 
(WHO), in 2019 only 50 antibiotics in the world were in clinical development [17], which is 
not sufficient to combat the increasing appearance of antibacterial-resistant organisms. 
Antibiotic resistance was already observed by Fleming in 1929, when he identified some 
bacterial strains whose growth was not inhibited by penicillin [18]. In the mid-1940s, when 
streptomycin was clinically used for the treatment of tuberculosis, resistant strains of 
Mycobacterium tuberculosis were also identified [19,20]. Today, we encounter a bigger 
problem: many pathogens causing serious nosocomial (hospital-linked) infections are 
becoming multidrug resistant, giving rise to high mortality and morbidity rates, as no 
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effective therapeutic options are available for the treatment of these diseases [21]. Both 
Gram-positive and Gram-negative bacteria are included in this dangerous group, the so-
called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) 
[22]. Therefore, in the last years, some projects have been launched to propel the discovery 
of new classes of antibiotics and to confront the worldwide health threat of antimicrobial 
resistance [23,24]. The main focus of these initiatives is directed towards NPs, which still 
remain the preferred source for the search of anti-infective agents. 
In summary, regarding the rapidly developing antibacterial-resistant pathogens, it is clear 
that there is an urgent need for new antibiotics to replace the current ineffective ones. NPs 
have demonstrated a broader structural and bioactive diversity and proven to be more 
efficient antimicrobials than chemically synthesized compounds. Therefore, promotion of NP 
discovery programs and exploitation of underexplored niches is mandatory to efficiently 
fight the incipient rise of resistant pathogens. 
 
1.2. Novel approaches for natural product discovery 
Traditionally, the preferred source of natural compounds has been soil bacteria, more 
specifically the filamentous bacteria actinomycetes, whose most promising genus is 
Streptomyces. In fact, 80% of the antibiotics used nowadays are derive from NPs synthesized 
by Streptomyces bacteria, including aminoglycosides (neomycin), carbapenem (doripenem), 
tetracyclines (chlortetracycline), and modified peptides (vancomycin, daptomycin), among 
others [25,26]. Since soil sampling is easy and inexpensive, terrestrial actinomycetes as well 
as their secondary metabolism products have been well characterised, frequently leading to 
the rediscovery of common species and already known compounds. Moreover, horizontal 
gene transfer occurring among actinomycetes contributes to the production of similar 
metabolic profiles in different species [27], limiting the structural diversity of NPs found in a 
specific area. Therefore, researchers have recently focused on alternative sources of NPs, 
primarily marine environments such as sea depths, coral reefs, salt lakes, polar regions, or 
fjord sediments [28-31]. The extreme conditions of these habitats force bacteria to adapt 
their metabolism by expressing genes that are usually silent under the milder conditions of 
terrestrial ecosystems. In many cases, the activation of these genes leads to the production 
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of novel bioactive secondary metabolites that represent interesting drug candidates. Many 
promising compounds have been isolated from marine bacteria, e.g. haloduracin, a broad-
spectrum two-peptide lantibiotic isolated from Bacillus halodurans growing at an alkaline pH 
of >9.0 [32]; marinopyrroles A and B from a Streptomyces sp. collected at the coast of La 
Jolla, California, harbouring significant antimicrobial activity against methicillin-resistant 
Staphylococcus aureus [33], or kiamycin, an angucyclinone showing cytotoxic activity, 
isolated from Streptomyces griseus M268 in a marine sediment [34]. It is estimated that 
marine environments contain around 1.2 x 1029 prokaryotic cells/ml, suggesting the 
enormous potential of these niches to provide interesting natural structures [35]. 
Nevertheless, only up to 0.1% of the marine microbes and about 1% of all bacteria (both 
terrestrial and aquatic) is believed to be cultivable in the laboratory [36,37]. To overcome 
this problem, metagenomic approaches were introduced in the late 1990s, allowing the 
direct isolation of DNA from the environment, which can be further cloned and analysed in 
other bacterial species [38]. At the same time, DNA sequencing techniques started to 
become faster and more economic, turning metagenomics into a successful tool for the 
discovery of NP biosynthetic genes and their corresponding products [39]. 
Among the bacteria that are easily cultivable in the laboratory are actinomycetes. The 
genome sequencing of several actinomycete strains showed that these microorganisms 
harbour a great amount of secondary metabolite biosynthetic genes [40-43]. This finding 
demonstrates that the capacity of actinomycetes to produce bioactive compounds is even 
bigger than estimated from their expressed metabolome, and that the majority of secondary 
metabolites encoded in these bacteria remain undiscovered. 
The genes responsible for the biosynthesis of secondary metabolites in bacteria are 
arranged in clusters. The expression of these clusters is not always achieved in the 
laboratory, since the applied growth conditions generally cannot mimic the complex 
environment and often extreme changes occurring in nature. Therefore, many of the 
secondary metabolite biosynthetic gene clusters (BGCs) encoded in the genomes of 
actinobacteria are cryptic (silent) under conventional laboratory conditions. Several 
strategies for the activation of silent secondary metabolite BGCs have been developed. They 
are classified in multiple-effect approaches and cluster-specific approaches. The methods 
with multiple effects involve the expression of many genes and generate global metabolic 
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changes in the cell. They include the OSMAC method (One Strain Many Compounds), where 
the production of several compounds can be activated by altering the cultivation conditions 
[44-46]; co-cultivation of different microorganisms [47]; manipulation of pleiotropic 
regulators [48,49], and upregulation of the transcription and translation machineries [50,51]. 
In contrast, the cluster-specific strategies provide a tighter control of gene expression and 
are focused on a particular BGC for which the gene organisation and transcriptional 
regulatory mechanisms are known. Among these methods are engineering of pathway-
specific regulators, i.e., inducing the expression of transcriptional activators or deleting 
repressor genes [52,53], and refactoring of BGCs, which consists in exchanging the native 
inactive promoters for constitutive promoters that lead to upregulation of specific 
biosynthetic genes [54,55]. Refactoring of BGCs is often coupled with expression in a 
heterologous host suitable for genetic manipulation, especially if the original producer is not 
genetically amenable. Heterologous expression has become a useful tool for revealing the 
NPs encoded by many cryptic gene clusters. 
 
1.3. Heterologous expression of secondary metabolite BGCs 
Since the Hopwood group characterised the complete genome sequence of Streptomyces 
coelicolor and discovered that it encodes more secondary metabolite BGCs than previously 
expected [41], the idea of genome mining started to germinate. Genome mining consists in 
screening the genome sequence of microorganisms in the search for NP biosynthetic gene 
clusters. The increasing availability of genome sequence information, triggered by the new 
inexpensive next-generation sequencing techniques [56], has promoted the development of 
softwares able to predict gene clusters potentially involved in the synthesis of secondary 
metabolites, such as PRISM, antiSMASH, and BiG-SCAPE [57-59]. Heterologous expression 
facilitates the discovery of NPs produced by the BGCs identified through genome mining. 
The expression of BGCs in a heterologous strain has numerous advantages. First of all, it 
facilitates the deciphering of orphan clusters, since the new compounds produced by a host 
microorganism can be attributed to the introduced genes [60,61]. Second, the commonly 
reduced metabolic background of modified host strains increases the availability of 
precursors, which are more efficiently channelled into the heterologous biosynthetic 
pathway. Moreover, the relatively simple metabolic profile accelerates the identification and 
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purification process of new secondary metabolites [62-64]. Third, the use of genetically 
amenable hosts enables the refactoring of the introduced gene clusters to activate their 
expression (e.g., promoter replacement, upregulation of transcriptional activators, deletion 
of repressors) [55,65,66] or to generate derivatives that might display new biological 
activities (combinatorial biosynthesis) [67-69]. Heterologous expression also allows for 
mobilisation of metagenomic DNA into a cultured surrogate strain, broadening the discovery 
of secondary metabolites to underexplored niches like unculturable bacteria [70,71]. Finally, 
unconventional BGCs that could not be directly detected by commonly used genome mining 
tools can be eventually identified through heterologous expression of DNA fragments from a 
genomic library, revealing the so far unknown biosynthetic routes of previously discovered 
NPs [72,73]. Briefly, heterologous expression of secondary metabolite BGCs represents a 
promising strategy for the discovery of new microbial NPs, the characterization of 
biosynthetic pathways, and the expansion of diversity of chemical structures and 
bioactivities. 
 Nonetheless, some challenges must be addressed when performing heterologous 
expression. Secondary metabolite gene clusters present a wide range of sizes: from a few kb 
to more than 100 kb. The vectors used for mobilisation of gene clusters into heterologous 
hosts can carry a limited size of DNA insert [74]. For small clusters, such as those of lasso 
peptides (2-5 kb), plasmid vectors may be utilised [75]. In cases where the BGCs of interest 
are bigger than 10 kb, genomic libraries based on cosmid vectors can be constructed, with 
the subsequent screening for clones that harbour the desired BGCs [76,77]. However, these 
vectors are limited to 40-50 kb inserts, which might not cover a complete gene cluster. A 
strategy to solve this limitation is the assembly of inserts cloned in different vectors into a 
single cosmid, resulting in reconstitution of the full gene cluster [78,79]. A significant 
drawback of this approach is that cosmid vectors become unstable with such large inserts. 
An alternative to the reassembly of BGCs is the use of bacterial artificial chromosomes 
(BACs) for the creation of genomic libraries with a capacity of >100 kb per clone. Both BAC 
and cosmid vectors are amenable to genetic manipulation in E. coli before being transferred 
to the final heterologous host for BGC expression [80]. 
Although heterologous expression often leads to acceptable production levels of the 
desired compound, in many occasions the yield is lower than that of the original producer 
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[81,82]. Some of the reasons for such low production levels might be the incompatibility of 
transcriptional regulators between the native and heterologous hosts, differences in 
precursor supply, toxicity of compounds expressed by the introduced gene cluster, or the 
absence of essential cofactors in the host strain. Therefore, genetic engineering of the 
heterologous gene cluster and/or the host strain is commonly performed to increase the 
yield of the final product and to facilitate its analysis [83-85]. 
 
1.4. Heterologous hosts for natural product discovery 
Traditionally, well-established laboratory strains such as E. coli and B. subtilis have been 
used in biotechnology for the production of recombinant proteins and other primary 
metabolites [86,87]. However, the nature of these strains makes them unsuitable for the 
efficient production of secondary metabolites. They generally do not produce sufficient 
amounts of the precursors necessary for the biosynthesis of NPs, they lack resistance genes 
against antibiotics, their regulatory systems are different than those of NP original 
producers, and very often they cannot properly fold the biosynthetic enzymes of secondary 
metabolites. In contrast, other bacterial strains such as those of the genus Streptomyces are 
well known to produce a varied collection of NPs, thus representing a more convenient host 
for heterologous expression of these compounds. An optimal host organism for the 
expression of secondary metabolite BGCs and the discovery of new NPs should exhibit the 
following features: (a) rapid growth rate; (b) genetic tractability; (c) varied and abundant 
production of precursors; (d) great capability to express heterologous BGCs; (e) clean 
metabolic background with low production of native secondary metabolites; and (f) high 
production yields of the desired compound. 
Currently, many efforts are being directed to develop optimal Streptomyces host strains 
that can efficiently express foreign BGCs and produce sufficient amounts of the compounds 
of interest to facilitate their purification and characterisation. One of the main obstacles of 
using streptomycetes as hosts is that they encode a high number of native secondary 
metabolite biosynthetic pathways, which compete for resources with the heterologous gene 
clusters, resulting in low yields of the desired product. To overcome this problem, many 
optimisation strategies have focused on diminishing the native secondary metabolism of 
heterologous hosts, creating cluster-free chassis strains [88]. It has been discovered that the 
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subtelomeric regions of three Streptomyces genomes, S. avermitilis, S. coelicolor A3(2) and 
S. griseus, contain unconserved non-essential genes, mostly secondary metabolite genes 
that could be removed without affecting the growth of the bacterium [42]. Genome 
reduction, often combined with other genetic manipulations, has been performed in several 
Streptomyces hosts, resulting in optimised heterologous strains. 
Streptomyces coelicolor has been for decades the model organism of streptomycetes. Its 
genome was the first one of the genus to be sequenced [41] and it is the best genetically 
characterised Streptomyces strain [89]. A wide range of tools are available to genetically 
manipulate the organism, including protocols for transformation and conjugation, well-
established replicative and integrative vectors, several promoters for gene expression, 
terminators, and reporter genes [90]. S. coelicolor encodes over 40 secondary metabolite 
BGCs that produce actinorhodin (act), undecylprodigiosin (red), calcium-dependant 
antibiotic (cda), and coelimycin (cpk), among other compounds. Many heterologous NP gene 
clusters have been successfully expressed in S. coelicolor or in engineered strains derived 
from the wild type [90-92]. 
The first modification made on S. coelicolor was the deletion of the act cluster and 
mutation of the red cluster, resulting in the strain S. coelicolor CH999, which is unable to 
produce both actinorhodin and undecylprodigiosin [93]. This strain was developed for the 
heterologous production of polyketides, such as the antitumor compound neocarzilin and 
the antiparasitic drug frenolicin B [94,95]. Another modified strain also deficient in 
producing actinorhodin and undecylprodigiosin is S. coelicolor M512, which was initially 
created to characterise the regulation of the biosynthesis of these compounds [96]. For that, 
the pathway-specific transcriptional activator genes, actII-ORF4 and red, were deleted. 
Heterologous expression of the antibiotic clorobiocin gene cluster in S. coelicolor M512, 
together with genetic engineering of its biosynthetic pathway led to the production of some 
new analogues of the compound [97]. The generation of a chassis strain, S. coelicolor 
M1146, was achieved by deletion of the secondary metabolite gene clusters act, red, cda, 
and cpk from the wild type S. coelicolor M145 [98]. This strain was designed for optimising 
the heterologous expression of BGCs and facilitating the identification of the synthesised 
products. For instance, the gene cluster of the antibiotic coumermycin A1 was successfully 
expressed in S. coelicolor M1146, producing 7.5 times more compound than S. coelicolor 
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M512 [99]. Additionally, mutated rpoB and rpsL genes were introduced in S. coelicolor 
M1146, giving rise to the strains S. coelicolor M1152 and M1154 [98]. These mutated genes 
have been previously reported to improve the production levels of secondary metabolites 
[100]. The heterologous production of roseoflavin, desotamides, streptocollin, 
chroramphenicol, and congocidin, among others, was successfully achieved in S. coelicolor 
M1152 and M1154, which in most of the cases produced higher levels of the compounds 
than the parental strain S. coelicolor M1146 [73,98,101,102]. Subsequently, the three native 
type III polyketide synthase (PKS) genes of S. coelicolor M1152 were removed to generate 
the cluster-free strain S. coelicolor M1317 [103]. The type III PKS genes responsible for the 
production of germicidins were heterologously expressed in this strain, yielding 30% more 
production of the compounds than the parental strain S. coelicolor M1152 [103]. 
Streptomyces avermitilis is a well-studied microorganism used for industrial production 
the antiparasitic compound avermectin [104]. It is genetically stable and amenable and 
genetic manipulation toolkits are well established in S. avermitilis [105,106]. Therefore, it 
represents a promising candidate for the heterologous production of secondary metabolites. 
The Ikeda group constructed several genome-minimised strains derived from S. avermitilis. 
For instance, they created the large-deletion mutants SUKA2 and SUKA3, both lacking a 1.5-
Mb region containing the gene clusters for avermectin and filipin, two of the main secondary 
metabolites of the organism. Additionally, they removed the biosynthetic genes for 
oligomycin, another polyketide related to avermectin, resulting in the chassis strains 
S. avermitilis SUKA4 and SUKA5 [104]. The SUKA5 strain was further modified by deletion of 
the BGCs of the terpenes geosmin, neopentalenolactone, and carotenoid, generating the 
strains S. avermitilis SUKA17 and SUKA22 [107]. The biosynthetic genes for the compounds 
oxytetracycline, resistomycin, nemadectin, and cephamycin C, among others, have been 
heterologously expressed in these strains, obtaining increased levels of these NPs in 
comparison to the wild type S. avermitilis or the original producer [107]. 
Streptomyces lividans is genetically related to S. coelicolor and has an exceptional feature 
of producing low levels of internal proteases, which makes it an ideal host for the expression 
of recombinant proteins [108]. Additionally, S. lividans has been successfully used as a host 
for the production of peptide-derived secondary metabolites, such as daptomycin, viomycin, 
labyrinthopeptins, and polycyclic tetramate macrolactams (PTMs) [109-112]. Several strains 
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based on the wild type S. lividans 66 have been engineered to improve the expression of 
heterologous NP gene clusters. 
The most commonly used S. lividans-derived strain is S. lividans TK24, which lacks the 
endogenous plasmids SLP2 and SLP3 and contains the point mutation [K88E] in the rpsL 
gene, which is known to enhance the production of secondary metabolites [113]. S. lividans 
TK24 has been used as a heterologous host for identification of the antibiotic berninamycin 
BGC, synthesis of analogues of the insecticide spinosyn, and investigation of the metabolic 
pathway leading from the aminoglycoside antibiotic paromamine to kanamycin derivatives 
[114-116]. Deletion of the actinorhodin biosynthetic genes (act) from S. lividans TK24 
generated the isogenic strains S. lividans K4-114 and K4-155. A temperature-sensitive vector 
was used for substitution of the act genes with a resistance gene in S. lividans K4-114, while 
a suicidal vector was introduced in K4-155 [117]. Heterologous expression and 
characterisation of the gene clusters of several compounds have been performed in the 
hosts S. lividans K4-114 and K4-155, such as the macrolide antibiotic oleandomycin and the 
aromatic polyketide enterocin gene cluster [62,118]. Moreover, a whole set of genome-
reduced strains has been developed for the efficient heterologous expression of the 
mithramycin A BGC. The so called RedStrep host strains are deficient in the production of 
several native secondary metabolite gene clusters, and an increase of 3-fold in the 
production levels of mithramycin A was reported in one of the strains, compared to the 
parental strain S. lividans TK24 [85]. Recently, three new chassis strains, S. lividans ΔYA9, S. 
lividans ΔYA10 and S. lividans ΔYA11, were generated by deletion of up to 11 endogenous 
secondary metabolite gene clusters and the subsequent introduction of additional attB sites 
for integration of heterologous clusters [119]. These strains showed a better yield of the 
heterologously produced tunicamycin, deoxycinnamycin, and griseorhodin than S. lividans 
TK24 [119]. 
Streptomyces albus has been used in the past for studying the restriction endonuclease 
system and its ability to cleave bacteriophage DNA [120,121]. It has a fast growth rate (4 
days in agar medium) and successful heterologous expression of many secondary metabolite 
BGCs has been reported in this strain [122]. Genetic manipulation toolkits for cloning and 
expression of genes are well established in S. albus. The strain S. albus J1074 is the most 
commonly used S. albus-based heterologous host. It was derived from the wild type S. albus 
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G by removal of the SalI restriction modification system [123] and it shows better 
conjugation efficiency than the parental strain. S. albus J1074 also synthesizes diverse 
precursors that enable the successful heterologous production of numerous secondary 
metabolites, e.g., landomycin, fredericamycin, grecocycline, lysolipin, rebeccamycin, and 
paulomycin [78,124-128]. In many cases, S. albus J1074 synthesizes higher levels of the 
heterologously produced compound than the original producer or other heterologous hosts. 
For instance, the yield of the herbicidal compounds thaxtomins was improved by 12 times in 
S. albus J1074 in comparison to the parental strain, and the antitumor agent iso-migrastatin 
was produced in titres 2-fold higher in S. albus J1074 than in S. coelicolor M-512 and S. 
lividans K4-114 [129,130]. Additionally, S. albus J1074 could successfully express BGCs from 
metagenomic DNA, a feature that is not commonly found in other heterologous hosts [131-
134]. 
The strain S. albus J1074 has been further engineered by overexpression of the crp gene 
that codes for the pleiotropic regulator CRP (cAMP receptor protein) which promotes the 
synthesis of secondary metabolites [135]. Moreover, it has been reported that deletion of 
the phosphofructokinase gene (pfk) in S. coelicolor A3(2) leads to increased production of 
actinorhodin through redirection of the carbon flux towards the production of NADPH, 
which is necessary for the biosynthesis of secondary metabolites (Borodina, 2008). 
Therefore, the gene pfk was deleted in the S. albus strain overexpressing crp, resulting in 
S. albus Δpfk+crp. The heterologous production of actinorhodin was tested in both strains, 
S. albus+crp and S. albus Δpfk+crp, leading to an increased yield of 1.5 and 2-fold, 
respectively, when compared to S. albus J1074 [135]. 
The creation of a chassis strain derived from S. albus J1074 has been recently reported. A 
total of 15 native secondary metabolite BGCs, including all the PKS, NRPS, lanthipeptide, and 
glycoside antibiotic gene clusters, have been removed, resulting in the strain S. albus Del14 
[64]. This strain displays a metabolic profile remarkably simpler than that of S. albus J1074, 
which is a huge advantage for the identification and purification of heterologously produced 
compounds. The new host was tested by expressing the gene clusters of various natural 
products: the polyketides didesmethylmensacarcin, aloesaponarin II, and pyridinopyrone A, 
the nucleoside antibiotic tunicamycin, and the ribosomally synthesised and post-
translational modified peptide (RiPP) cinnamycin. The production yield of all of them was 
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significantly higher in the cluster-free strain S. albus Del14 than in the parental S. albus 
J1074. S. albus Del14 was further modified by introduction of additional attB sites, allowing 
the insertion of a higher copy number of gene clusters. The strains S. albus B2P1 and S. albus 
B4, carrying 3 and 4 attB sites, respectively, were created. Most of the compounds produced 
in these strains through heterologous expression showed improved yields in comparison to 
those of the parental strain S. albus J1074 [64]. 
NPs are highly diverse molecules synthesized by complex biosynthetic pathways. Many 
factors influence the successful activation of their biosynthetic genes and their production. It 
has been demonstrated that the transfer of secondary metabolite gene clusters to optimized 
heterologous hosts very frequently results in production of the corresponding compounds. A 
wide variety of heterologous hosts derived from several Streptomyces species has been 
developed for the expression of foreign gene clusters. Due to the varied nature of BGCs and 
their specific requirements for activation of transcription, the expression of a particular gene 
cluster might be triggered in a heterologous strain but not in others. The creation of a 
universal host strain for the expression of any type of BGC remains rather utopic and efforts 
in optimizing heterologous hosts need to focus on adapt to the specific features of each 
gene cluster. 
 
1.5. Outline of the work 
The main goal of this thesis was the characterization of cryptic gene clusters and 
identification of new NPs encoded in the genome of the marine actinomycete 
Streptomyces albus subsp. chlorinus. Heterologous expression of a BGC in a host strain 
allowed the identification of the nybomycin biosynthetic genes and led to the production of 
a new structure. Additionally, selection of streptomycin-resistant mutants of S. albus ssp. 
chlorinus resulted in activation of a type II PKS gene cluster and overproduction of the novel 
polyketide fredericamycin C2. 
As described in Publication I (Chapter 2), a cryptic BGC from S. albus ssp. chlorinus was 
heterologously expressed in the chassis strain S. albus Del14, leading to the production of 
the previously described antibiotic nybomycin. The homology between the heterologously 
expressed genes and the structurally related compound streptonigrin BGC led us to propose 
a biosynthesis pathway for nybomcyin. The identification of nybomycin BGC (nyb genes) 
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provides a better understanding of its biosynthesis and enables the potential generation of 
analogues with new bioactivities. 
Besides nybomycin, heterologous expression of the nyb genes also yielded a novel 
compound, benzanthric acid (Publication II, Chapter 2). The new metabolite was found 
neither in the extract of the nybomycin original producer S. albus ssp. chlorinus nor in that of 
the host strain S. albus Del14. This suggests that benzanthric acid might be the product of 
interplay between the introduced nyb pathway and the host´s metabolism. 
Finally, a streptomycin-resistant mutant was obtained from S. albus subsp. chlorinus 
(Publication III, Chapter 2). The mutant strain, S. albus subsp. chlorinus JR1, showed high 
production levels of the novel polyketide fredericamycin C2, which expands the structural 
diversity of the fredericamycin family. A type II PKS gene cluster was confirmed to be 
responsible for the biosynthesis of this compound after heterologous expression in the host 
strain S. albus Del14. We propose that a frameshift point mutation causing a deficiency of 
the RsmG protein is responsible for both the increased production of fredericamycin C2 and 
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Abstract: Streptomycetes represent an important reservoir of active secondary metabolites with
potential applications in the pharmaceutical industry. The gene clusters responsible for their
production are often cryptic under laboratory growth conditions. Characterization of these clusters
is therefore essential for the discovery of new microbial pharmaceutical drugs. Here, we report the
identification of the previously uncharacterized nybomycin gene cluster from the marine actinomycete
Streptomyces albus subsp. chlorinus through its heterologous expression. Nybomycin has previously
been reported to act against quinolone-resistant Staphylococcus aureus strains harboring a mutated
gyrA gene but not against those with intact gyrA. The nybomycin-resistant mutants generated from
quinolone-resistant mutants have been reported to be caused by a back-mutation in the gyrA gene that
restores susceptibility to quinolones. On the basis of gene function assignment from bioinformatics
analysis, we suggest a model for nybomycin biosynthesis.
Keywords: streptomycetes; secondary metabolites; nybomycin gene cluster; heterologous expression;
nybomycin biosynthesis
1. Introduction
Actinobacteria represent a prominent source of natural products with potential industrial
applications. The genus Streptomyces is especially well known to produce a diverse spectrum of
compounds with antibacterial, antifungal, antitumor and even insecticide and herbicide activity [1–3].
The increasing amount of sequenced microbial genomes has provided insight into the unprecedented
potential of actinobacteria to biosynthesize natural products [4,5]. Generally, dozens of various
secondary metabolite clusters are encoded in their genomes. However, these clusters are often
poorly expressed under standard cultivation conditions or even remain silent, thus preventing
the isolation and characterization of the encoded compounds. Such uncharacterized clusters
with unknown biosynthetic products are usually regarded as cryptic. Different approaches can
be used to characterize cryptic clusters, including changing cultivation parameters (OSMAC
approach), expression of pleiotropic regulatory genes, introduction of antibiotic-resistant mutations,
and refactoring of the biosynthetic pathways [6–9]. Currently, characterization of the cryptic gene
clusters encoding natural products often relies on expression of their biosynthetic pathways in
the optimized surrogate strains called heterologous hosts or chassis strains. The heterologous
expression approach has a number of advantages compared to other cluster characterization methods.
The simplified metabolic background of the chassis strains facilitates the identification of natural
Mar. Drugs 2018, 16, 435; doi:10.3390/md16110435 www.mdpi.com/journal/marinedrugs
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products; fast DNA-recombineering methods in E. coli and DNA transfer methods into streptomycetes
simplify biosynthetic studies, and high production yields enable product supply for structure
elucidation and biological activity studies.
In this study, we report the identification and characterization of the previously uncharacterized
nybomycin gene cluster from the marine strain Streptomyces albus subsp. chlorinus NRRL B-24108
through heterologous expression in Streptomyces albus Del14. Nybomycin was first isolated in 1955;
however, the unique biological activity of the antibiotic was discovered only recently [10]. Nybomycin
inhibits growth of quinolone-resistant Staphylococcus aureus by targeting the mutated enzyme gyrase.
Interestingly, the intact gyrase encoded by the gyrA gene without the resistance mutation is not
inhibited by the antibiotic. The rare nybomycin-resistant mutants derived from quinolone-resistant
S. aureus have all been reported to contain the reverse mutation in the gyrA gene, causing loss of
quinolone resistance. Despite this interesting mode of action, the biosynthetic gene cluster leading
to nybomycin production remains unknown. Based on the cluster analysis, we also propose the
biosynthetic route leading to the production of nybomycin.
2. Results
Identification of the Nybomycin Gene Cluster through Its Heterologous Expression
In the course of systematic activation of cryptic secondary metabolite clusters from Streptomyces
albus subsp. chlorinus NRRL B-24108 [3], a cluster annotated by the antiSMASH genome mining
software [11] as “fatty acid metabolism cluster” was expressed in the heterologous host strains. For this
purpose, a BAC 4N24 containing the cluster was isolated from the previously constructed genomic
library of S. albus subsp. chlorinus and transferred into Streptomyces albus Del14 and Streptomyces lividans
TK24 [12,13]. The obtained exconjugant strains Streptomyces albus 4N24 and Streptomyces lividans 4N24
as well as the corresponding control strains without the BAC S. albus Del14 and S. lividans TK24
were fermented in the production medium. LC-MS analysis of the exconjugant strains containing
the heterologous cluster confirmed its successful expression in S. albus 4N24, as indicated by a new
peak that was observed in the extract of the strain (Figure 1A,B and Figure S1). Expression of the
cluster in S. lividans 4N24 did not lead to the production of any new compounds compared with the
control strain.
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Figure 1. LC-MS chro t s of crude xtracts from S. albus 4N2 and S. albus Del14. The new peak
found in S. albus 4N24 crude extract is indicated with an asterisk (*). (A) Base peak chromatograms;
(B) extracted ion chromatograms (299.10 ± 0.1 Da); (C) mass spectrum associated to tR = 4.7 min from
S. albus 4N24 LC-MS chromatogram.
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Analysis of the S. albus 4N24 extract by high-resolution MS analysis revealed that the identified
peak corresponded to the compound with an [M + H]+ of 299.102 m/z and the deduced molecular
formula C16H15N2O4 (Figure 1C). A search in a natural product database revealed that the identified
compound might correspond to the antibiotic nybomycin (Figure 2). To verify this, a nybomycin
standard (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used. LC-MS analysis of the pure
nybomycin, the S. albus 4N24 extract, and the S. albus 4N24 extract spiked with pure nybomycin
confirmed that the new compound corresponded to nybomycin; the retention time and the mass
spectrum of the new compound were identical to those of the pure standard (Figure S2). Additionally,
to validate the identity of the detected compound as nybomycin, the former was purified. For this
purpose, S. albus 4N24 was inoculated into 10 L of DNPM medium, and the culture broth of the strain
was extracted with ethyl acetate. The compound was purified from the extract using normal-phase,
size-exclusion, and reverse-phase chromatography. The purified compound, as well as the pure
nybomycin standard, was used for NMR measurements. The recorded 1H-NMR spectra of the purified
compound and of nybomycin were identical (Table S1; Figure S3), which unambiguously proved the
identity of the former as nybomycin.
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core structure for nybomycin and streptonigrin are highlighted in red.
BAC 4N24, which contains the nybomycin biosynthetic genes, comprises a 36 kb genomic DNA
region with 33 open reading frames (Figure 3, Table 1). A sequence similarity search revealed that nine
open reading frames within this region shared homology at the protein level with the genes involved
in the biosynthesis of streptonigrin, which is structurally related to nybomycin (Figure 2). Sequence
analysis of the DNA fragment cloned in BAC 4N24 revealed the putative streptomycin-resistant gene,
a hypothetical gene, a gene encoding an ATP-binding protein, and four additional hypothetical genes
followed by the nybA gene encoding a putative 3-carboxy-cis,cis-muconate cycloisomerase at its 5’
end (Table 1), which implied that the nybA gene might constitute the 5’ end of the nybomycin cluster.
The 3’ end of the cloned region comprised the genes encoding a putative methyltransferase, two
isopenicillin N synthases, a transporter, three transcriptional regulators, and a hypothetical protein
(nybS, nybT, nybU, nybV, nybW, nybX, nybZ, and nybY, respectively). To clarify whether these genes
were part of the nybomycin biosynthetic cluster, two BACs 4M14 and 6M11 that partially overlap with
BAC 4N24 were isolated from the genomic library of S. albus subsp. chlorinus and expressed in S. albus
Del14. Both the isolated 4M14 and 6M11 BACs completely covered the 5’ end of the fragment cloned
in the original BAC 4N24, which led to nybomycin production. Compared with BAC 4N24, BAC 4M14
lacked the region downstream of the nybR gene, while BAC 6M11 lacked the region downstream
of the nybL gene (Figure 3). The obtained strains S. albus 4M14 and S. albus 6M11 were analyzed
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together with S. albus 4N24 for nybomycin production. During the LC-MS analysis, no nybomycin was
detected in the extracts of either the S. albus 4M14 or S. albus 6M11 strains (Figure S4). Nybomycin was
readily detectable in the extract of S. albus 4N24. These results give evidence that the 3’-terminal region
of 4N24, which contains the genes downstream of nybR (nybS to nybZ), is essential for nybomycin
production. Taken together, our results suggest that the genes from nybA to nybZ might constitute the
nybomycin gene cluster, which is further supported by the fact that the genes from nybA to nybF and
nybN to nybP share high levels of homology with genes in the biosynthetic cluster of streptonigrin
(Table 1), a compound that is structurally similar to nybomycin (Figure 2).
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orf-06 159 Hypothetical protein WP_027736486.1 86/93 - - 
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(AFW04562.1) 
66/75 
nybC 325 NADPH:quinone reductase WP_066029240.1 81/87 stnH1 (AFW04558.1) 63/71 
nybD 638 Anthranilate synthase WP_079145437.1 81/87 stnM1 
(AFW04564.1) 
65/75 
nybE 227 Isochorismatase WP_066029243.1 84/89 
stnM2 
(AFW04565.1) 66/76 
nybF 402 DAHP synthase WP_066029245.1 81/87 stnM3 (AFW04567.1) 62/69 
nybG 279 Hypothetical protein - - - - 
nybH 257 Vicinal oxygen chelate protein WP_066029246.1 64/72 - - 
nybI 222 NAD(P)H:dehydrogenase WP_066029248.1 90/95 - - 
nybJ 135 Hypothetical protein WP_066029250.1 76/86 - - 
nybK 266 N-acetyltransferase WP_066029251.1 80/88 - - 
nybL 333 Amidohydrolase WP_066029254.1 84/90 - - 
nybM 354 Acetoacetyl-CoA synthase WP_066029256.1 82/87 - - 
nybN 182 Aromatase/cyclase WP_066029258.1 78/85 stnI (AFW04559.1) 54/67 
nybO 550 Long-chain acyl-CoA synthetase WP_066029260.1 85/90 stnJ (AFW04560.1) 68/81 
nybP 476 Salicylate hydroxylase WP_079145438.0 74/79 
stnH2 
(AFW04561.1) 62/72 
nybQ 376 Hypothetical protein WP_030685222.1 57/69 - - 
nybR 238 NAD-dependent epimerase WP_066029265.1 82/89 - - 
nybS 253 
SAM-dependent 
methyltransferase WP_079145439.1 89/94 - - 
nybT 333 Isopenicillin N synthase family oxygenase WP_078974705.1 80/89 - - 
nybU 342 Isopenicillin N synthase family 
oxygenase 
WP_078974705.1 72/83 - - 
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orf-07 268 Streptomycin 3”-adenylyltransferase WP_037865927.1 71/77 - -
orf-06 159 Hypothetical protein WP_027736486.1 86/93 - -
orf-05 163 ATP-binding protein WP_052413949.1 76/83 - -
orf-04 332 Hypothetical protein WP_055499466.1 74/82 - -
orf-03 341 Hypothetical protein WP_030379123.1 71/80 - -
orf-02 494 Hypothetical protein WP_078869279.1 70/81 - -
orf-01 242 Hypothetical protein - - - -
nybA 475 3-carboxy-cis,cis-muconate cycloisomerase WP_066029238.1 66/85 stnL (AFW04563.1) 71/76
nybB 669 FAD-binding protein WP_066029239.1 77/84 stnK1 (AFW04562.1) 66/75
nybC 325 NADPH:quinone reductase WP_066029240.1 81/87 stnH1 (AFW04558.1) 63/71
nybD 638 An hr nilate synthase WP_079145437.1 81/87 stnM1 (AFW04564.1) 65/75
nybE 227 Isochorismatase WP_066029243.1 84/89 stnM2 (AFW04565.1) 66/76
nybF 402 DAHP synthase WP_066029245.1 81/87 stnM3 (AFW04567.1) 62/69
nybG 279 Hypothetical protein - - - -
nybH 257 Vicinal oxygen chelate protein WP_066029246.1 64/72 - -
nybI 222 NAD(P)H:dehydrogenase WP_066029248.1 90/95 - -
nybJ 135 Hypothetical protein WP_066029250.1 76/86 - -
nybK 266 N-acetyltransferase WP_066029251.1 80/88 - -
nybL 333 Amidohydrolase WP_066029254.1 84/90 - -
nybM 354 Acetoacetyl-CoA synthase WP_066029256.1 82/87 - -
nybN 182 Aromatase/cyclase WP_066029258.1 78/85 stnI (AFW04559.1) 54/67
nybO 550 Long-chain acyl-CoA synthetase WP_066029260.1 85/90 stnJ (AFW04560.1) 68/81
nybP 476 Salicylate hydroxylase WP_079145438.0 74/79 stnH2 (AFW04561.1) 62/72
nybQ 376 Hypothetical protein WP_030685222.1 57/69 - -
nybR 238 NAD-dependent epimerase WP_066029265.1 82/89 - -
nybS 253 SAM-dependent methyltransferase WP_079145439.1 89/94 - -
nybT 333 Isopenicillin N synthase family oxygenase WP_078974705.1 80/89 - -
nybU 342 Isopenicillin N synthase family oxygenase WP_078974705.1 72/83 - -
nybV 495 MFS transporter WP_079145411.1 81/87 - -
nybW 243 Transcriptional regulator WP_079145410.1 82/93 - -
nybX 197 Transcriptional regulator WP_025356654.1 89/93 - -
nybY 87 Hypothetical protein WP_086560781.1 68/81 - -
nybZ 219 Transcriptional regulator WP_0576 3815.1 79/86 - -
1 NCBI accession numbers are given. 2 NCBI accession numbers are shown in parentheses.
3. Discussion
The antibiotic nybomycin was discovered in 1955 in the culture broth of streptomycetes A 717 [14].
The structural features of ybomycin as a fused pyridoquinolone ring system and an angularly fused
oxazoline ring are of particular biosynthetic interest as they have not been reported for other natural
products [15]. Despite the unique structure of nybomycin, its biosynthetic cluster and biosynthetic route
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have remained elusive. Only the results of feeding studies imply that acetate, methionine, and some
non-identified shikimate-type intermediates serve as biosynthetic precursors for nybomycin [15,16].
In this article, we have described the identification of the nybomycin biosynthetic gene cluster from the
marine streptomycete S. albus subsp. chlorinus NRRL B-24108 through its expression in the cluster-free
heterologous host S. albus Del14.
Sequence analysis of the DNA fragment cloned in BAC 4N24 has revealed that a number of
genes within this fragment are highly homologous to the genes involved in biosynthesis of the
antibiotic streptonigrin (Table 1) [17]. Direct comparison of nybomycin and streptonigrin has shown
distinct structural similarity, with both structures containing a diamino-substituted, six-membered
ring (Figure 2). The structural similarity and the partial homology of the gene clusters suggest that
nybomycin and streptonigrin biosynthetic routes can have some similar biosynthetic intermediates
and enzymatic reactions.
Based on the sequence analysis and the results of BAC expression, we propose that the genes
nybA to nybZ constitute the nybomycin gene cluster. The nybA gene, encoding a putative 3-carboxy-cis,
cis-muconate cycloisomerase, is homologous to the streptonigrin biosynthetic gene stnL. The nybZ gene
encodes a putative transcriptional regulator that might also participate in nybomycin biosynthesis.
Similar to the streptonigrin pathway, the 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP)
synthase encoded by nybF is likely to catalyze the first reaction in the nybomycin biosynthetic
route. DAHP synthase is responsible for the first reaction of the shikimate pathway—biosynthesis of
3-deoxy-D-arabino-hept-2-ulosonate 7-phosphate (DAHP) from phosphoenolpyruvate and D-erythrose
4-phosphate (Figure 4) which is supported by the results of feeding experiments that have
demonstrated that the carbons of the central ring of nybomycin are derived from a shikimate-type
intermediate [15]. Catalyzing the first reaction, DAHP synthase regulates the amount of carbon
entering the shikimate pathway and therefore can be responsible for its upregulation to provide
sufficient amounts of biosynthetic precursors for nybomycin. The genes encoding enzymes responsible
for the conversion of DAHP into chorismate are absent in the nybomycin cluster and in the
streptonigrin pathway [17]. Therefore, the host’s primary metabolism enzymes most likely overtake
these biosynthetic steps. We propose that the second reaction catalyzed by the enzymes encoded
in the biosynthetic cluster is the conversion of chorismate into 4-aminoanthranilic acid (Figure 4),
which is a key intermediate in both nybomycin and streptonigrin biosynthesis (Figure 2). Isolation of
4-aminoanthranilic acid from the culture broth of the streptonigrin producer Streptomyces flocculus
supports this suggestion [18]. Furthermore, 4-aminoanthranilic acid has also been shown to incorporate
into streptonigrin [18]. We propose that the products of the nybC, nybD, nybE, and nybL genes
might be responsible for the conversion of chorismate into 4-aminoanthranilic acid. The nybL
gene, encoding putative amidohydrolase [19], has no homologue in the streptonigrin biosynthetic
pathway. We suggest that the protein product of nybL may provide enough supply of ammonia for
the amination of chorismate by anthranilate synthase [20], encoded by nybD, during the biosynthesis
of 4-aminoanthranilic acid. In the streptonigrin biosynthesis, the function of the nybL gene may be
overtaken by the one of the host’s primary metabolism enzymes.
After formation of 4-aminoanthranilic acid, it is then hydroxylated in the third position and
decarboxylated, generating 2,6-diaminophenol (Figure 4). The nybP gene encoding putative salicylate
hydroxylase might be responsible for the hydroxylation reaction. Then, two acetoacetate units are
attached to the amino groups of 2,6-diaminophenol through the action of the N-acetyltransferase
encoded by the nybK gene (Figure 4). The putative acetoacetyl-CoA synthase encoded by the nybM gene
catalyses the formation of acetoacetyl-CoA from acetyl-CoA and malonyl-CoA. The NybM enzyme is
likely responsible for the production of sufficient amounts of acetoacetate, which is used as a precursor
in nybomycin biosynthesis. The precursor role of acetoacetate in nybomycin biosynthesis is supported
by the results of the feeding experiments, which have unequivocally defined acetate as the source of the
exterior carbons of the pyridone rings [16]. We speculate that after attachment of the acetoacetate units,
the putative cyclase encoded by the nybN gene catalyses the closure of the pyridone rings, leading to
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formation of intermediate 1 (Figure 4). The methylation of nitrogen within the pyridone rings is likely
to be catalyzed by the SAM-dependent methyltransferase encoded by nybS. We hypothesize that the
next reaction in nybomycin biosynthesis is a closure of the oxazoline ring (Figure 4). This step might
be catalyzed by the product of nybT or nybU, which code for isopenicillin N synthases (IPNS). IPNS is
responsible for the biosynthesis of isopenicillin N through a bicyclization reaction—first, the formation
of a C-N bond generates a β-lactam ring; then, the closure of a five-membered thiazolidine ring is
accomplished by the formation of a C-S bond [21]. Sulfur and oxygen have similar properties [22].
Therefore, in a similar way to thiazolidine ring closure, IPNS could be able to catalyze the formation of
a C-O bond between the carbon atom of the N-methyl group and the oxygen atom of the OH group
present in intermediate 2, generating an oxazoline ring (Figure 4). Finally, a hydroxylation reaction
takes place at C-8’, possibly catalyzed by the oxidoreductase NybB, giving rise to nybomycin final
structure. The compound is then secreted to the extracellular space, most likely by the membrane
transporter encoded by nybV. Expression of secondary metabolite biosynthesis genes is commonly
regulated by activators and repressors coded by genes that are located within the same cluster.
We hypothesize that the products of nybW, nybX, and nybZ, which encode putative transcriptional
regulators, might control the expression of the genes involved in nybomycin biosynthesis.Mar. Drug  2018, 16, x FOR PEER REVIEW  7 of 10 
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In this paper we report the identification of the gene cluster encoding production of the structurally
unique antibiotic nybomycin. Biological activity of nybomycin is also of particular interest as it inhibits
growth of quinolone-resistant Staphylococcus aureus, dormant Mycobacterium tuberculosis, and other
Gram-positive and Gram-negative bacteria [10,14,23]. Interestingly, nybomycin targets solely the
mutant, quinolone-resistant DNA gyrase with a Ser84Leu substitution, while it is inactive against the
wild-type, quinolone-sensitive form of the enzyme [10]. The mutation described thus far to cause
nybomycin resistance is a reverse Leu84Ser mutation within the gyrA gene that restores quinolone
sensitivity. The identification of the nybomycin cluster presented in this paper enables biosynthetic
studies of nybomycin production, generation of new nybomycin derivatives, and optimization of
its production as well as a nybomycin supply for further biological studies. Together, these works
might help fight the development of quinolone resistance and revive quinolones as an effective class
of antibiotics.
4. Materials and Methods
4.1. General Experimental Procedures
All strains and BACs used in this work are listed in Table S2. Escherichia coli strains were cultured
in LB medium [24]. Streptomyces strains were grown on soya flour mannitol agar (MS agar) [25] for
sporulation and conjugation and in liquid tryptic soy broth (TSB; Sigma-Aldrich, St. Louis, MO, USA).
For secondary metabolite expression, liquid DNPM medium (40 g/L dextrin, 7.5 g/L soytone, 5 g/L
baking yeast, and 21 g/L MOPS, pH 6.8) was used. The antibiotics kanamycin, apramycin and nalidixic
acid were supplemented when required.
4.2. Isolation and Manipulation of DNA
BAC extraction from a Streptomyces albus subsp. chlorinus constructed genomic library
(Intact Genomics, USA), DNA manipulation, E. coli transformation, and E. coli/Streptomyces
intergeneric conjugation were performed according to standard protocols [24–26]. Plasmid DNA
was purified with the BACMAX™ DNA purification kit (Lucigen, Middleton, WI, USA). Restriction
endonucleases were used according to manufacturer’s recommendations (New England Biolabs,
Ipswich, MA, USA).
4.3. Metabolite Extraction and Analysis
Streptomyces strains were grown in 10 mL of TSB for 1 day, and 1 mL of each culture was used to
inoculate 50 mL of production medium. Cultures were grown for 7 days at 28 ◦C. Metabolites were
extracted with ethyl acetate from the supernatant, evaporated, and dissolved in methanol. One µL of
each sample was separated using a Dionex Ultimate 3000 UPLC (Thermo Fisher Scientific, Waltham,
MA, USA), a 10-cm ACQUITY UPLC® BEH C18 column, 1.7 µm (Waters, Milford, MA, USA) and a
linear gradient of 0.1% formic acid solution in acetonitrile against 0.1% formic acid solution in water
from 5% to 95% in 18 min at a flow rate of 0.6 mL/min. Samples were analyzed using an amaZon speed
mass spectrometer or maXis high-resolution LC-QTOF system (Bruker, USA). Data were collected
and analyzed with the Bruker Compass Data Analysis software, version 4.1 (Bruker, Billerica, MA,
USA). Monoisotopic mass was searched in the natural product database DNP (Dictionary of Natural
Products [27]).
4.4. Nybomycin Isolation and 1H-NMR Spectroscopy
Streptomyces albus 4N24 was grown in 30 mL of TSB for 1 day, and 1 mL of the preculture was
used to inoculate 100 flasks containing 100 mL of DNPM medium. Cultures were incubated at 28 ◦C
for 7 days. Metabolites from the supernatant were extracted as described above. The crude extract
was fractionated by normal phase chromatography on a prepacked silica cartridge (Biotage, Uppsala,
Sweden) using hexane, dichloromethane, ethyl acetate, and methanol as the mobile phase. Fractions
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containing nybomycin were detected by LC-MS analysis. They were pooled together, evaporated,
and dissolved in methanol. The sample was further separated by size-exclusion chromatography on an
LH 20 Sephadex column (Sigma-Aldrich, USA) using methanol as the solvent. Finally, the sample was
separated by semipreparative HPLC (Dionex UltiMate 3000, Thermo Fisher Scientific, USA) using a
C18 column (Synergi 10 µm, 250 × 10 mm; Phenomenex, Aschaffenburg, Germany) and a 0.1% formic
acid solution in acetonitrile as the mobile phase to obtain nybomycin (0.1 mg). Individual peaks were
collected and analyzed by LC-MS as described above. The 1H-NMR spectra were recorded on a Bruker
Avance 500 spectrometer (Bruker, BioSpin GmbH, Rheinstetten, Germany) at 300 K equipped with
a 5 mm BBO probe using deuterated trifluoroacetic acid (Deutero, Kastellaun, Germany) as solvent
containing tetramethylsilane (TMS) as a reference. The chemical shifts were reported in parts per
million (ppm) relative to TMS. All spectra were recorded with the standard 1H pulse program using
128 scans.
4.5. Genome Mining and Bioinformatics Analysis
The S. albus subsp. chlorinus genome was screened for secondary metabolite biosynthetic gene
clusters using the antiSMASH [11] online tool (https://antismash.secondarymetabolites.org/#!/start)
and the software Geneious 11.0.3 [28]. The DNA sequence of the nybomycin gene cluster was deposited
into GenBank under accession number MH924838.
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Figure S3: 1H-NMR spectra of a nybomycin standard and nybomycin isolated from S. albus 4N24; Figure S4:
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Tables 






Isolated nybomycin Standard nybomycin 
Position δH Position δH 
2 6.77 s 2 6.77 s 
5 7.09 s 5 7.09 s 
6’ 2.81 s 6’ 2.81 s 
7 7.67 s 7 7.67 s 
8’ 5.52 s 8’ 5.52 s 
9 8.10 s 9 8.10 s 
11’ 4.47 s 11’ 4.47 s 
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Table S2. Bacterial strains and BACs used in this work. 
Bacterial strain Features Reference/Source 
Streptomyces albus subsp. 
chlorinus NRRL B-24108 
S. albus subspecies strain harboring 
nybomycin biosynthetic gene cluster 
[1] 
Streptomyces albus Del14 Wild-type strain [2] 
Streptomyces albus 4N24 S. albus strain with BAC 4N24 insertion This work 
Streptomyces albus 4M14 S. albus strain with BAC 4M14 insertion This work 
Streptomyces albus 6M11 S. albus strain with BAC 6M11 insertion This work 
Streptomyces lividans TK24 Wild-type strain [3] 
Streptomyces lividans 4N24 S. lividans strain with BAC 4N24 insertion This work 
Escherichia coli ET12567 pUB307 Donor strain for intergeneric conjugation [4] 
Escherichia coli DH10β General cloning strain [5] 
BACs   
pSMART AmR; BAC vector Lucigen (USA) 
4N24/4M14/6M11 BACs containing full or partial nybomycin gene cluster This work 




Figure S1. UV chromatograms of crude extracts from S. albus 4N24 and S. albus Del14. The new peak found in 




Figure S2. Comparison of LC-MS chromatograms at tR = 4.1 min of Streptomyces albus 4N24 crude extract and a 
nybomycin standard. (A) Extracted ion chromatograms (299.10 ± 0.1 Da) of crude extract from S. albus 4N24 
supplemented with 0.05 mg/ml of pure nybomycin, crude extract from S. albus 4N24 broth culture, a 0.05 mg/ml 
nybomycin solution in methanol, and crude extract from S. albus Del14 broth culture. (B) Mass spectra 
associated to the peak at tR = 4.1 min from the three upper chromatograms displayed in (A). 
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Figure S3. 1H-NMR (500 MHz, d-TFA) spectra of a nybomycin standard and nybomycin isolated from S. albus 
4N24. 1H-NMR spectra of nybomycin standard (A) and the isolated nybomycin (B) are identical. 
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Figure S4. Extracted ion chromatograms of S. albus 4M14, S. albus 6M11, and S. albus 4N24 crude extracts. 
Nybomycin appears only in S. albus 4N24 crude extract, which shows a peak at tR = 4.7 min (indicated with an 
asterisk) comprising an [M+H]+ of 299.102 m/z (mass spectrum not shown). 
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Streptomycetes constitute a diverse bacterial group able to produce a wide variety of
secondary metabolites with potential applications in the pharmacy industry. However, the
genes responsible for the biosynthesis of these compounds are very frequently inactive or
expressed at very low levels under standard laboratory cultivation conditions. Therefore,
the activation or upregulation of secondary metabolite biosynthesis genes is a crucial
step for the discovery of new bioactive natural products. We have recently reported
the discovery of the biosynthetic genes for the antibiotic nybomycin (nyb genes) in
Streptomyces albus subsp. chlorinus. The nyb genes were expressed in the heterologous
host Streptomyces albus Del14, which produces not only nybomycin, but also a novel
compound. In this study, we describe the isolation, purification, and structure elucidation
of the new substance named benzanthric acid.
Keywords: benzanthric acid, biosynthetic gene cluster, heterologous expression, nybomycin, secondary
metabolite, Streptomyces
INTRODUCTION
Numerous species of the actinomycetal genus Streptomyces harbor metabolic pathways that
produce secondary metabolites with a broad spectrum of bioactivities, which in many cases
represent potential drug leads for the development of pharmaceuticals (Paulus et al., 2017; Protasov
et al., 2017). The biosynthetic genes for these metabolites are generally arranged in clusters whose
expression is often very low under laboratory cultivation conditions. Therefore, diverse strategies
have been developed in order to induce the biosynthesis of natural products in Streptomyces strains
(McKenzie et al., 2010; Olano et al., 2014; English et al., 2017). A widely used approach consists in
the heterologous expression of a specific gene cluster in an optimized host strain where some of the
native secondary metabolite genes have been removed (Myronovskyi et al., 2018; Bu et al., 2019).
The simplified metabolic background promotes the channeling of biosynthetic precursors toward
the production of the heterologous metabolites and facilitates their identification.
The marine strain Streptomyces albus subsp. chlorinus NRRL B-24108 is responsible for the
production of bioactive metabolites such as the herbicide albucidin and the antibiotic nybomycin
(Hahn et al., 2009; Rodriguez Estevez et al., 2018). We have recently discovered the biosynthetic
genes for nybomycin (nyb genes) in S. albus subsp. chlorinus through a heterologous expression
approach using the chassis strain Streptomyces albusDel14 as a host (Rodriguez Estevez et al., 2018).
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Besides nybomycin, we detected a new metabolite in the extract
of S. albus 4N24 expressing the nyb genes. In this study, we report
the isolation, purification and structure elucidation of the novel




Streptomyces and Escherichia coli strains used in this work
are listed in Supplementary Table 1. LB medium was used
for cultivation of E. coli strains according to standard
protocols (Green and Sambrook, 2012). Streptomyces strains were
cultivated in standard media (Kieser et al., 2000): soy flour
mannitol agar (MS agar) and liquid tryptic soy broth (TSB;
Sigma-Aldrich, St. Louis, MO, USA). Additionally, liquid DNPM
medium (40 g/L dextrin, 7.5 g/L soytone, 5 g/L baking yeast,
and 21 g/L MOPS, pH 6.8) was used for secondary metabolite
expression. The following antibiotics were supplemented when
required at concentrations of 50 µg/µl (solid medium) or 25
µg/µl (liquid medium): kanamycin, apramycin, and nalidixic
acid (Carl Roth, Germany; Sigma-Aldrich, USA).
Isolation and Manipulation of DNA
Bacterial artificial chromosome (BAC) 4N24 was isolated
from a library comprising the genome of Streptomyces albus
subsp. chlorinus (Intact Genomics, St. Louis, MO, USA).
DNA manipulations and cloning procedures including E.
coli transformation and intergeneric conjugation between E.
coli/Streptomyces were performed following standard protocols
(Kieser et al., 2000; Green and Sambrook, 2012; Rebets et al.,
2017). Plasmid DNA was purified with the BACMAX
TM
DNA
purification kit (Lucigen, Middleton, WI, USA). Restriction
endonucleases were used for plasmid diagnostic test (New
England Biolabs, Ipswich, MA, USA).
Metabolite Extraction and Analysis
Streptomyces albus 4N24 as well as the control strains
Streptomyces albus De14 and Streptomyces albus subsp. chlorinus
were cultivated in 15mL TSB medium for 24 h at 28◦C. Main
cultures containing 50mL of DNPM were inoculated with 1mL
of pre-culture. After 7 days of cultivation at 28◦C, the secreted
metabolites were extracted with ethyl acetate and butanol,
followed by solvent evaporation. The dry extracts were solved
in 1mL methanol and 1 µL of the solved sample was separated
using a Dionex Ultimate 3000 UPLC (Thermo Fisher Scientific,
Waltham, MA, USA), and a 10-cm ACQUITY UPLC R© BEH
C18 column, 1.7µm (Waters, Milford, MA, USA). The mobile
phase was comprised of two solvents: formic acid solved in
acetonitrile (0.1%) and formic acid solved in water (0.1%).
Solvent concentrations varied in a linear gradient from 5 to 95%
in 18min at a flow rate of 0.6 mL/min. The UPLC system was
coupled either to amaZon speed mass spectrometer or maXis
high-resolution LC-QTOF system (Bruker, USA), allowing the
mass spectrometry analysis of the extracts. The software Bruker
Compass Data Analysis version 4.1 (Bruker, Billerica, MA, USA)
was used for data analysis. Monoisotopic mass was searched
in the natural product database DNP (Dictionary of Natural
Products; Buckingham, 1993).
Benzanthric Acid Isolation and Nuclear
Magnetic Resonance (NMR) Spectroscopy
A flask containing 30mL TSB medium was inoculated with S.
albus 4N24 and incubated at 28◦C for 24 h. The production
culture consisted of 10 L divided into 100 flasks, each containing
100mL DNPM medium and inoculated with 1mL of pre-
culture. After 7 days of cultivation at 28◦C, metabolite extraction
was performed as described above. The crude extract was
fractionated by size-exclusion chromatography on an LH
20 Sephadex column (Sigma-Aldrich, USA) using methanol
as the mobile phase. Resulting fractions were analyzed by
LC-MS and those containing benzanthric acid were further
separated by preparative HPLC (Waters 2545 Binary Gradient
module, Waters, Milford, MA, USA) using a Nucleodur R© C18
HTec column (5µm, 250 × 21mm, Macherey-Nagel, Düren,
Germany) with a linear gradient of 0.1% formic acid solution
in methanol against 0.1% formic acid solution in water, yielding
5mg of benzanthric acid. UV spectra were recorded with
a PAD detector (Photodiode Array Detector, Waters 2998,
Waters, Milford, MA, USA). All reported NMR spectra were
recorded at 298K on a Bruker Avance 500 with a 5mm
BBO probe (Bruker, BioSpin GmbH, Rheinstetten, Germany)
using DMSO-d6 (deuterated dimethyl sulfoxide) as solvent.
The solvent peak was used as an internal standard and set
to δH 2.49 for the
1H-NMR and δC 39.50 for the
13C-NMR,
respectively. For the structural elucidation the following spectra
were recorded with standard pulse programs: 1H-NMR, 13C-
NMR, 1H-1H-correlated spectroscopy (COZY), heteronuclear
single quantum spectroscopy (HSQC), heteronuclear multiple
bond correlation (HMBC), and rotating frame Overhauser
enhancement spectroscopy (ROESY, spin-lock: 300 ms).
Feeding Experiment With Anthranilic Acid
(Phenyl-13C6)
Two flasks containing 25mL of DNPM medium were
inoculated with S. albus 4N24 as described above (Section
Metabolite Extraction and Analysis). One of the cultures
was supplemented with 5 mg/mL of anthranilic acid
(phenyl-13C6) (Cambridge Isotope Laboratories, Andover,
MA, USA) at intervals of 12 h for 4 days, while the
second one was used as a control. After further 24 h
cultivation, the metabolites were extracted from the
supernatant as described in Section Metabolite Extraction
and Analysis.
Antimicrobial Susceptibility Test
Susceptibility tests were performed by the disk diffusion
method described in Bauer et al. (1966). Ten mL of LB
soft agar (10 g/l tryptone, 10 g/l NaCl, 5 g/l yeast extract,
7 g/l agar) were inoculated with the strains Escherichia coli
GB2005, Bacillus subtilis ATCC 6633 or Pseudomonas putida
KT2440 and poured on LB agar plates. Four paper disks
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(Macherey and Nagel, Düren, Germany) were coated with
100, 50, 10, and 0.5 µg of benzanthric acid solved in
DMSO, respectively, and placed onto the solidified soft agar.
DMSO was used as a negative control and the antibiotics
ampicillin, chloramphenicol, and nalidixic acid (50 mg/mL,
respectively) as positive controls. The plates were incubated at
28◦C overnight.
Herbicidal Pre-emergence Test
Seeds ofAgrostis stolonifera (JuliwaHESA, Heidelberg, Germany)
were placed into the wells of a 96-well microtiter plate (Sarstedt,
Nümbrecht, Germany). A solution containing 2.2 g/l Murashige
& Skoog plant salts (Serva, Heidelberg, Germany) and 1.6 g/l
Gamborg’s B5 plant medium (Serva, Heidelberg, Germany) was
added to the wells. Decreasing concentrations of benzanthric
acid solved in DMSO were added (2mM, 1mM, 0.5mM,
0.25mM, 125µM, and 62.5µM). Identical volumes of DMSO
without benzanthric acid were used as a toxicity test of the
organic solvent. The solution containing the plant medium
was used as a negative control. The plate was closed and
incubated at room temperature under constant light (Osram
Fluora lamp) in a humidity chamber. After 3 days of incubation,
the plate lid was removed and a container with tap water was
placed inside the chamber for increasing the air humidity. The
plate was incubated up to 6 days. Three technical replicates
were performed.
Genome Mining and Bioinformatics
Analysis
The online tool antiSMASH (https://antismash.
secondarymetabolites.org/#!/start) was used for the
identification of secondary metabolite biosynthetic gene
clusters in the genome of S. albus subsp. chlorinus
(Weber et al., 2015). Gene cluster analysis was
performed with the help of the software Geneious 11.0.3
(Kearse et al., 2012).
FIGURE 1 | HPLC-MS analysis of benzanthric acid production. (A) Base peak chromatograms of crude extracts from the parent strain S. albus subsp. chlorinus, the
recombinant strain S. albus 4N24 harboring the nybomycin gene cluster and the host strain S. albus Del14. Peaks corresponding to benzanthric acid and nybomycin
are indicated by 1 and 2, respectively. (B) UV spectrum of benzanthric acid. (C) Mass spectrum of benzanthric acid (m/z 256.0 [M+H]+). The signal at m/z 238.0
corresponds to the [M+H-H2O]
+ ion and the signal at m/z 511.1 corresponds to the [2M+H]+ ion.
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RESULTS
We have previously reported the identification of the nybomycin
gene cluster from S. albus subsp. chlorinus NRRL B-24108
through heterologous expression of BAC 4N24 harboring the
nyb genes in the host S. albus Del14 (Rodriguez Estevez
et al., 2018). In addition to nybomycin, the HPLC-MS
analysis of an extract from the recombinant strain S. albus
4N24 expressing the nyb genes revealed the presence of
a peak at tR = 6.9min and m/z 256.059 [M + H]
+
(Figure 1), exhibiting UV absorption signals at λmax 237,
282, 320, and 386 nm (Figure 1B). Unlike nybomycin, which
is produced by both S. albus 4N24 and the parent strain
S. albus subsp. chlorinus, the peak at m/z 256.059 was
solely detected in the extract of S. albus 4N24 (Figure 1).
The search of the monoisotopic mass 255.051 in a natural
product database yielded no coincidences, which suggested a
putatively new compound and encouraged us to purify it for
structure elucidation.
After seven days of cultivation of the strain S. albus 4N24
in 10 L of DNPM liquid medium, the broth was centrifuged
and the metabolites were extracted from the supernatant. The
extract was fractionated by size-exclusion chromatography
through a Sephadex column followed by preparative high
performance liquid chromatography (HPLC) to yield 5mg
of the novel metabolite benzanthric acid (Figure 2A). The
molecular formula of benzanthric acid was determined
as C14H9NO4 by high-resolution electrospray ionization
mass spectrometry (HRESMS) and NMR (m/z 256.05949,
−3.688 ppm). The analysis of the 13C-NMR (125 MHz,
DMSO-d6) revealed the presence of fourteen carbons. Two
carbons were assigned as carbonyl groups (δC 168.67 C-1,
160.22 C-9). The twelve remaining carbons were assigned as
olefinic carbons (δC 135.28 C-6, 133.40 C-5a, 129.95[2x] C7
& C8, 122.58 C-5, 122.34 C-4a, 121.52 C-8a, 118.57 C-10,
113.29 C-2, 108.84 C-4) including one oxygenated carbon
(δC 140.59 C-9a) and one aminated carbon (δC 147.81 C-
3; Supplementary Figures 1–3). The 1H-NMR (500 MHz,
DMSO-d6) showed six aromatic signals: δH 8.24 (1H, dd;
J1,2 = 7.9, 1.1Hz; H-8), δH 8.16 (1H, d, J = 8.1Hz, H-5), δH
7.96 (1H, dt, J1,2 =7.7, 1.1Hz, H-6), δH 7.70 (1H, dt, J1,2 =
7.6, 0.6Hz, H-7), δH 7.64 (1H, s, H-10), and δH 7.57 (1H,
s, H-4; Supplementary Figures 1, 4–6). The 1H-1H-COZY
spectrum showed correlations between H-5 and H-6, H-6
and H-7, H-7, and H-8 (Supplementary Figures 7, 8). The
phase sensitive HSQC spectrum revealed eight quaternary
carbons (C-1, C-2, C-3, C-4a, C-5a, C-8a, C-9, and C-
9a; Supplementary Figures 9, 10). Through correlation
in the heteronuclear multiple bond correlation (HMBC)
experiment connections between the spin systems were







1 168.67C – – –
2 113.29C – – –
3 147.81C – – –
4 108.84 CH 7.57 s – C-1, C-2, C-3,
C-5a, C-9a, C-10
4a 122.34C – – –
5a 133.40C – – –
5 122.58 CH 8.16 d (8.1) 6 C-4a, C-5a, C-6,
C-8, C-8a, C-9
6 135.28 CH 7.96 dt (7.7,
1.1)
5; 7 C-5a, C-7, C-8
7 129.95 CH 7.70 dt (7.6,
0.6)
6; 8 C-5, C-5a, C-6,
C-8, C-8a, C-9
8 129.95 CH 8.24 dd (7.9,
1.1)
7 C-5a, C-6, C-9
8a 121.52C – – –
9 160.22C – – –
9a 140.59C – – –
10 118.57 CH 7.64 s – C-1, C-2, C-4,
C-4a, C-5a, C-9a,
C-10
COOHd – 7.00–9.50 s br – –
NHd2 – 7.00–9.50 s br – –
a125 MHz for 13C-NMR.
b500 MHz for 1H-NMR.
cHMBC correlations from protons to the indicated carbons.
dExchangeable protons.
FIGURE 2 | Chemical structures of (A) benzanthric acid, (B) nybomycin and (C) anthranilic acid.
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FIGURE 3 | Analysis of anthranilic acid (phenyl-13C6) incorporation. (A) Mass spectrum of benzanthric acid (m/z 255.9 [M+H]
+) extracted from the culture of S. albus
4N24. The signal at m/z 237.9 corresponds to the [M+H-H2O]
+ ion. (B) Mass spectrum of benzanthric acid extracted from the culture of S. albus 4N24 fed with
anthranilic acid (phenyl-13C6). The signal at m/z 262.0 corresponds to the [M+H]
+ ion after incorporation of the labeled anthranilic acid. (C) Mass spectrum of
nybomycin (m/z 299.0 [M+H]+) extracted from the culture of S. albus 4N24. (D) Mass spectrum of nybomycin extracted from the culture of S. albus 4N24 fed with
anthranilic acid (phenyl-13C6). No incorporation of anthranilic acid can be detected.
identified (Supplementary Figures 11, 12). The complete
list including all correlations can be found in Table 1.
Important correlations to establish connections between
the spin systems were H-4 to C-5a, H5 to C-4a as well as
H-10 to C-4a and C-4. A 15N-HMBC experiment revealed
the correlation between H-4 and the nitrogen of the primary
aromatic amine (Supplementary Figure 13). The ROESY
spectrum showed a correlation through space between H-4 and
H-5 (Supplementary Figure 14).
Benzanthric acid’s structure has been determined as a
benzoate part bound to an anthranilatemoiety. This arrangement
considerably differs from the core structure of nybomycin
(Figures 2A,B), which is also produced by the strain S. albus
4N24 harboring the nyb genes. In order to test whether
anthranilic acid functions as a precursor in the biosynthesis of
benzanthric acid and nybomycin, a culture of S. albus 4N24
was fed with anthranilic acid (phenyl-13C6) (Figure 2C). HPLC-
MS analysis of the resulting extract revealed the incorporation
of the labeled anthranilate into the structure of benzanthric
acid. The mass spectrum of benzanthric acid shows two signals:
a signal at m/z 256 corresponding to the [M+H]+ ion of
the compound and a signal at m/z 238 corresponding to
its derivative after water loss (Figure 3A). After feeding with
labeled anthranilic acid an additional signal at m/z 262 is
observed (Figure 3B), implying the incorporation of the six 13C
atoms of the labeled anthranilate into benzanthric acid. No
incorporation of anthranilic acid into the structure of nybomycin
was detected (Figures 3C,D).
The antimicrobial activity of benzanthric acid against
the Gram-negative bacteria Escherichia coli and Pseudomonas
putida, as well as the Gram-positive bacterium Bacillus
subtilis was assayed through disk diffusion test, revealing no
growth inhibitory activity (Supplementary Figure 15A). The
herbicidal activity of the new metabolite was tested against
the monocot grass species Agrostis stolonifera. The purified
benzanthric acid was added to the plant seeds and incubated
in a minimal medium. Seed germination was observed after
3 days, indicating no inhibitory effect against the tested
plant (Supplementary Figure 15B).
DISCUSSION
In this paper, we describe the isolation and chemical structure
elucidation of the novel metabolite benzanthric acid, produced
by S. albus 4N24 containing the nybomycin biosynthetic
gene cluster. The strain simultaneously produces nybomycin
and benzanthric acid, suggesting that both compounds
might share common biosynthetic steps. The structure of
benzanthric acid (Figure 2A) suggests anthranilate and
benzoate as possible biosynthetic precursors. The precursor
role of anthranilic acid has been proved by feeding studies.
Interestingly, no incorporation of anthranilic acid into
nybomycin’s structure could be detected, indicating substantial
differences in the biosynthetic routes leading to nybomycin and
benzanthric acid.
In living organisms, anthranilic acid is mainly synthesized
either through the shikimate pathway or through the tryptophan
degradation pathway (Haslam, 1974; Kurnasov et al., 2003). One
of the nybomycin biosynthetic genes, nybF, encodes a putative 3-
Deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) synthase,
which catalyzes the first reaction of the shikimate pathway. Since
the DAHP synthase controls the amount of carbon entering
the pathway, the expression of the nybF gene can lead to
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its upregulation and increased intracellular concentrations of
benzanthric acid’s precursor—anthranilic acid. Additionally, the
product of the nybD gene shows homology at the protein level
with anthranilate synthase and might be also responsible for the
additional supply of anthranilic acid. In this case, anthranilic acid
is most probably only a by-product of the enzyme’s reaction, since
it was shown not to be a precursor of nybomycin biosynthesis.
We propose that benzoic acid serves as the second direct
precursor for benzanthric acid production. No genes which could
lead to the biosynthesis of benzoic acid were identified within
the DNA fragment containing the nybomycin cluster. Therefore,
it is likely that benzoic acid is provided by the metabolism of
the host strain S. albus Del14. The phenylalanine degradation
pathway could be responsible for the supply of this precursor
(Tabor and Tabor, 1970).
The attachment of benzoic acid to the anthranilate moiety
is necessary for the formation of benzanthric acid. The enzyme
catalyzing this biosynthetic step could not be identified within
the nybomycin gene cluster. We propose that the required
enzyme is encoded by the genome of the host strain S. albus
Del14. This is further supported by the data revealing no
production of benzanthric acid by the original nybomycin
producer (Figure 1A).
The fact that the new compound, benzanthric acid, could be
generated through the expression of the characterized nybomycin
gene cluster in the well-studied heterologous host S. albus Del14
is intriguing. The isolated compound can be found neither in
the extracts of the natural nybomycin producer nor in that of
the heterologous host S. albus Del14. Benzanthric acid is also
not a degradation product of nybomycin. The most plausible
explanation for the origin of the isolated compound is the
interplay between the host’s metabolism and the introduced
biosynthetic pathway. The isolation of benzanthric acid raises the
question of whether this is rather an exception or the integration
of foreign metabolic pathways or their parts into the host’s
metabolism can be used as a tool for the generation of new
natural products.
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Supplementary Table 1. Bacterial strains and BAC (bacterial artificial chromosome) vectors used in 
this work. 
Bacterial strain Features 
Reference/ 
Source 
Streptomyces albus subsp. 
chlorinus NRRL B-24108 
S. albus subspecies strain 
harboring nybomycin biosynthetic 
gene cluster 
(Hahn et al. 
2009) 
Streptomyces albus Del14 Wild-type strain 
(Myronovskyi 
et al. 2018) 
Streptomyces albus 4N24 
S. albus strain with BAC 4N24 
insertion 
(Rodriguez 
Estevez et al. 
2018) 
Escherichia coli ET12567 
pUB307 
Donor strain for 
intergeneric conjugation 
(Flett et al. 
1997) 
Escherichia coli DH10β General cloning strain 
(Grant et al. 
1990) 
BACs   
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Supplementary Figure 1. Structure of benzanthric acid including chemical shifts of protons and 
carbons. 
 
   
 
Supplementary Figure 2. 
13
C-NMR spectrum (125 MHz, DMSO-d6) of benzanthric acid. 
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Supplementary Figure 4. 
1
H-NMR spectrum (500 MHz, DMSO-d6) of benzanthric acid. 
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Supplementary Figure 6. 
1
H-NMR spectrum (500 MHz, DMSO-d6) of benzanthric acid with increased intensity.
   
 




H-COSY spectrum (DMSO-d6) of benzanthric acid. 
   
 




H-COSY spectrum (DMSO-d6) of benzanthric acid (7.2 ppm – 8.6 
ppm). 
 
   
 




Supplementary Figure 4. HSQC spectrum (DMSO-d6) of benzanthric acid (7.5 ppm – 8.3 ppm & 
105 ppm – 138 ppm). 
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Supplementary Figure 5. HMBC spectrum (DMSO-d6) of benzanthric acid (7.5 ppm – 8.3 ppm & 




Supplementary Figure 6. HMBC spectrum (DMSO-d6) of benzanthric acid (7.3 ppm – 8.5 ppm & 
105 ppm – 175 ppm). 
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Supplementary Figure 14. ROESY spectrum (DMSO-d6) of benzanthric acid. 
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Supplementary Figure 15. Antimicrobial and herbicidal bioactivity tests. (A) Disk diffusion assay 
against growth of Escherichia coli, Bacillus subtilis, and Pseudomonas putida. Paper disks 1, 2, 3, 
and 4 were coated with 100 μg, 50 μg, 10 μg, and 0.5 μg, respectively, of benzanthric acid solved in 
DMSO. Ap: ampicillin; Cm: chloramphenicol; NAL: nalidixic acid. (-): negative control (DMSO). 
(B) Herbicidal test against seed germination of the monocot grass plant Agrostis stolonifera. 
Decreasing concentrations of benzanthric acid solved in DMSO were applied (first column). Identical 
volumes of solvent without benzanthric acid were applied (second column). Growth inhibitory effect 
of DMSO is observed at volumes of 10 μl and 5 μl. Minimal medium for plant growth (see section 
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Abstract: Streptomycetes are an important source of natural products potentially applicable in
the pharmaceutical industry. Many of these drugs are secondary metabolites whose biosynthetic
genes are very often poorly expressed under laboratory cultivation conditions. In many cases,
antibiotic-resistant mutants exhibit increased production of natural drugs, which facilitates the
identification and isolation of new substances. In this study, we report the induction of a type II
polyketide synthase gene cluster in the marine strain Streptomyces albus subsp. chlorinus through
the selection of streptomycin-resistant mutants, resulting in overproduction of the novel compound
fredericamycin C2 (1). Fredericamycin C2 (1) is structurally related to the potent antitumor drug lead
fredericamycin A.
Keywords: antitumor; fredericamycin; overproduction; secondary metabolites; streptomycetes;
streptomycin-resistant; type II PKS
1. Introduction
The bacterial genus Streptomyces is well-known for producing a huge variety of bioactive
secondary metabolites with potential pharmaceutical applications [1,2]. The genes responsible for their
biosynthesis are generally clustered together. However, many of these biosynthetic genes are poorly or
not expressed (silent) under laboratory cultivation conditions. Thus, the activation of silent secondary
metabolite gene clusters is an essential step for the discovery of new natural drugs. A simple strategy
to activate or upregulate the expression of these genes consists in screening for antibiotic-resistant
mutants [3,4]. This approach is based on the work of Ochi and his team. They discovered that certain
mutations in the rpsL and rpoB genes, which code for the ribosomal protein S12 and the β-subunit of
RNA polymerase, respectively, lead to an altered gene product that confers resistance to streptomycin
(str mutants) or to rifampicin (rif mutants), respectively. The mutations in these genes also increase the
production of secondary metabolites in several Streptomyces strains [3–7]. Presumably, some of the str
and rpoB mutations give rise to diverse metabolic changes which typically occur during the stringent
response. The stringent response is triggered in E. coli [8] and other prokaryotic microorganisms [9,10]
under amino acid starvation conditions by the signaling molecule, guanosine tetraphosphate (ppGpp).
This molecule generates a series of physiological changes, including a significant decrease of protein
synthesis [11], downregulation of rRNA transcription [12], and activation of stationary-phase metabolic
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processes, such as the expression of secondary metabolite biosynthetic genes [9]. Thus, it is suggested
that the mutant gene products of rpsL and rpoB may be responsible for antibiotic overproduction,
mimicking the role of ppGpp in the stringent response [3–6].
In previous studies, the marine strain Streptomyces albus subsp. chlorinus NRRL B-24108 has been
shown to harbor genes for the production of several bioactive secondary metabolites, such as the
herbicide albucidin or the antibiotic nybomycin [13,14]. Here, we report the induction of a type II
polyketide synthase (PKS) gene cluster in S. albus subsp. chlorinus, leading to overproduction of the
novel compound fredericamycin C2 (1). This substance is structurally related to fredericamycin C
(2), a secondary metabolite first isolated in 1981, together with the compounds fredericamycin A and
fredericamycin B, from the culture broth of Streptomyces griseus ATCC 49344 [15]. All fredericamycin
variants known to date (A, B, C, C1, and E) share a similar structure that involves two aromatic
moieties, which in the case of fredericamycins A and E are linked by a rare stereogenic spiro carbon
center [16–18]. Fredericamycin A displays strong in vivo anticancer activity against several mammal
tumor cell lines [19], and it has been patented as an effective treatment for certain types of cancer
in humans [20]. Additionally, fredericamycins A, B, C, and C1 exhibit moderate antibacterial and
antifungal activities [19]. In this study, we present the generation of the high-level streptomycin-resistant
strain, Streptomyces albus subsp. chlorinus JR1, which overproduces the novel compound fredericamycin
C2 (1). We also describe the mutation likely causing this phenotype and propose the initial biosynthetic
steps of fredericamycin C2 (1), based on the gene cluster homology with that of fredericamycin A.
2. Results
2.1. High-Level Streptomycin-Resistant Mutant S. albus subsp. chlorinus Overproduces the Novel Compound
Fredericamycin C2
The strain S. albus subsp. chlorinus NRRL B-24108 was cultured in MS agar medium containing
increasing concentrations of streptomycin. After several rounds of selection, we isolated a
streptomycin-resistant colony that displayed a distinctive violet color when cultured on a solid
medium, in contrast to the characteristic white color of the parental strain (Figure 1). We named
the mutant strain S. albus subsp. chlorinus JR1. While the growth of the wild type of S. albus subsp.
chlorinus was inhibited by a streptomycin concentration of 50 µg/mL, the mutant strain was able
to grow in the presence of up to 200 µg/mL of antibiotic (Table S1). The metabolic profiles of both
strains were analyzed using liquid chromatography and mass spectrometry, revealing the presence of
a peak at tR = 12.7 min that corresponds to an [M + H]+ ion of m/z 521.107 and displays UV absorption
signals at λmax 195, 248, 274, 345, and 490 nm (Figure 2). The peak area revealed an over 50-fold
greater production of the corresponding compound by S. albus subsp. chlorinus JR1 compared to the
parental strain’s yield (Table S2, Figure S1). The search of this mass in a natural product database
yielded no coincidences, suggesting a potentially undescribed metabolite overproduced by S. albus
subsp. chlorinus JR1. The compound was extracted from a 2 l solid culture of S. albus subsp. chlorinus
JR1 and purified by normal phase chromatography through a silica column followed by reverse
phase chromatography.
Figure 1. Streptomyces albus subsp. chlorinus NRRL B-24108 (left) and Streptomyces albus subsp. chlorinus
JR1 (right) spores on MS agar medium.
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Figure 2. HPLC-MS analysis of crude extract from solid cultures of S. albus subsp. chlorinus JR1 (a) and
its parental strain S. albus subsp. chlorinus NRRL B-24108 (b). (A) UV chromatogram. The asterisk
(*) indicates the peak corresponding to fredericamycin C2 (1) at tR = 12.7 min. (B) Mass spectrum
associated with tR = 12.7 min from the UV chromatogram displayed in (A). (C) UV spectrum of purified
fredericamycin C2 (1).
The molecular formula of the substance was determined to be C27H20O11 based on high-resolution
MS (ESI) showing the quasi molecular ion m/z 521.107 ([M + H]+, calculated for C27H21O11). In the
proton NMR spectrum, two broad multiplets are visible at δH 2.63 (t, 6’-H2) and 2.79 (t, 7’-H2) ppm,
which are two neighbored methylene groups. All other signals are singlets: One methoxy group at δH
3.94 (6-OCH3), one additional methylene group at δH 4.06 (4’-H2), one methyl group at δH 2.17 (1”-H3),
and two methines at δH 6.52 (5’-H) and 6.88 (7-H). Moreover, broad singlets at δH 5.5, 12.8, and 13.2 ppm
indicate hydroxyl groups to be present in the molecule (Table 1). Typical quinone carbonyl signals at δC
186.9 (C-4) and 187.6 (C-9) are visible in the 13C-NMR spectrum. A signal at δC 169.3 ppm (C-1’) shows
an acid functionality which is attached at C-8’ proven from an HMBC (Heteronuclear Multiple Bond
Coherence) correlation C-1’/ 5’-H. A very weak signal at δH 204.1 ppm (C-3’) shows a ketone supported
by an HMBC cross-peak C-3’/1”-H3 (Table 1). This ketone is part of a propan-2-on sidechain which is
attached at C-6’ based on HMBC signals C-6’/4’-H2, C-6’/1”-H3, C-5’/4’-H2, and C-7’/4’-H2. The HMBC
signal C-6/6-OCH3 indicates the methoxy group to be attached at C-6 next to the aromatic proton 7-H.
One of the rings contains a CH2-CH2 moiety (C-6’-C7’) which is in ring D proven from HMBC signals
C-3/7’-H2, C-7a’/7’-H2, C-8’/7’-H2, C-7a’/6’-H2, and C-5a’/6’-H2 (Figure S2). Comparison to literature
shows high similarity of the new compound named fredericamycin C2 (1) to fredericamycin C (2) [17],
which differs only in the sidechain attached at C-6’ (fredericamycin C) and to KS-619-1 (3) [21] with a
different substitution pattern of the pentacyclic ring system (KS-619-1) (Figure 3).
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Table 1. NMR data of fredericamycin C2 (1) (600/150 MHz, DMSO-d6/Pyridine-d5 95:5, 35 ◦C, solvent
(DMSO) as internal reference).
Pos. a δC δH (J Hz) COSY b HMBC b ROESY b
9’ 164.3 5’-H
9a’ 115.3 4’-H2, 5’-H
3’ 140.7 4’-H2, (5’-H)
5’ 120.4 6.52 s (4‘-H2) 1J, 4’-H2, (5’-H), 6’-H2 4’-H2, 6’-H2, (7’-H2)
5a’ 144.3 5‘-H, 6‘-H2, 7‘-H2
6’ 28.8 2.63 br t (7Hz) 7’-H2 5’-H, 7’-H2 5’-H, 7’-H2
7’ 21.2 2.79 br t (7Hz) 6’-H2 6’-H2





5 148.8 c 7-H
6 157.6 6-OCH3, 7-H
6-OCH3 56.4 3.94 s 6-H 1J 7-H






2 = 8’ 136.3 (5’-H), 7’-H2
8a’ 121.0 5’-H
1’ 169.3 5’-H
4’ 49.5 4.06 s (5’-H, 1”-H3) 5’-H, (1”-H3) 5’-H, 1”-H3
3’ (204.1) d





a Numbering according to fredericamycin C (2); b weak signals in brackets; c from HMBC; d very weak signal in
carbon NMR spectrum.
Figure 3. Structures of fredericamycin C2 (1), fredericamycin C (2) and KS-619-1 (3).
2.2. Fredericamycin C2 Is Biosynthesized by a Type II PKS Gene Cluster
Fredericamycin C2 (1) is structurally related to other fredericamycin variants, such as C and A,
which are biosynthesized by a type II PKS gene cluster [22]. This suggests the involvement of a type II
PKS system in the production of fredericamycin C2 (1). Although a subclass of type I PKSs (iterative
type I PKSs) have also been reported to synthesize aromatic compounds [23–26], their products
are structurally smaller and simpler than the complex multicyclic metabolites produced by type II
PKSs [27]. The pentacyclic aromatic polyketide structure of fredericamycin C2 (1) (Figure 3) further
supports the assumption of type II PKS genes involved in its biosynthesis. The genome of S. albus
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subsp. chlorinus was screened for secondary metabolite genes, revealing the presence of one type II PKS
gene cluster. Based on protein BLAST analysis, we assigned the genes putative functions, which are
summarized in Table 2. To test whether the expression of these genes leads to fredericamycin C2
(1) production, BAC 2P5 containing the identified type II PKS cluster was isolated from a genomic
library of S. albus subsp. chlorinus NRRL B-24108 and transferred via intergeneric conjugation into
the heterologous host Streptomyces albus Del14. HPLC-MS analysis of the extract from the resulting
ex-conjugant S. albus 2P5 revealed the presence of a peak with identical retention time and m/z to those
of fredericamycin C2 (1), demonstrating that the type II PKS cluster from S. albus subsp chlorinus is
responsible for fredericamycin C2 (1) biosynthesis (Figure S3, Figure 2). BAC 2P5 comprises a 35 kb
genomic region containing a total of 37 open reading frames (ORFs), 10 of which share homology at
protein level with the fredericamycin A gene cluster from S. griseus (Table 2, Figure 4), which is also
responsible for fredericamycin C (2) biosynthesis [22]. The homologue genes include those coding
for the minimal PKS ketosynthase subunits (KSα and KSβ), two polyketide cyclases, four tailoring
enzymes, a transcriptional regulator, and a protein of unknown function. The gene similarity with
fredericamycin A cluster, together with the heterologous expression results (Figure S3), indicates the
relevance of these genes in fredericamycin C2 (1) biosynthesis.
Table 2. Proposed functions of genes present in the type II polyketide synthase (PKS) cluster of S. albus
subsp. chlorinus and homology with fredericamycin A gene cluster.










c2fdmA 406 Cytochrome P450 oxygenase WP_017596471.1 66/73 - -
c2fdmB 594 Monooxygenase WP_017596470.1 67/75 - -
c2fdmC 337 O-methyltransferase WP_043504920.1 42/55 - -
c2fdmD 620 Asparagine synthase WP_017596467.1 79/88 - -
c2fdmE 497 Monooxygenase WP_081620749.1 59/70 - -
c2fdmF 216 Polyketide cyclase REH43750.1 43/54 - -
c2fdmG 107 Monooxygenase WP_027732672.1 44/64 - -
c2fdmH 237 3-ketoacyl-ACP reductase WP_017596481.1 72/83 - -
c2fdmI 134 Polyketide cyclase WP_109361109.1 72/83 - -
c2fdmJ 389 O-methyltransferase WP_061257536.1 67/79 fdmN 56/70
c2fdmK 138 Oxidoreductase WP_020573863.1 56/68 - -
c2fdmL 263 Unknown WP_017596478.1 56/71 - -
c2fdmM 138 Oxidoreductase WP_017596477.1 70/85 - -
c2fdmN 150 Unknown WP_017596476.1 76/89 - -
c2fdmO 358 O-methyltransferase WP_043504920.1 40/54 - -
c2fdmP 169 Unknown WP_017596474.1 62/75 - -
c2fdmQ 113 Monooxygenase WP_017596454.1 65/76 - -
c2fdmR 454 Biotin carboxylase WP_017596455.1 80/87 - -
c2fdmS 175 Biotin carboxyl carrier protein WP_026120848.1 60/71 - -
c2fdmT 585 Carboxyl transferase WP_017596457.1 75/80 - -
c2fdmU 111 Monooxygenase WP_017596458.1 70/78 fdmQ 50/66
c2fdmV 113 Monooxygenase WP_017596459.1 76/83 fdmP 51/70
c2fdmW 248 3-ketoacyl-ACP reductase WP_017596460.1 83/92 fdmO 55/71
c2fdmX 153 Unknown WP_015621174.1 61/74 - -
c2fdmY 156 Polyketide cyclase WP_075740187.1 67/82 fdmI 56/74
c2fdmZ 87 ACP WP_017596463.1 46/71 - -
c2fdmA1 409 KSβ WP_017596464.1 77/86 fdmG 61/72
c2fdmB1 422 KSα WP_017596465.1 83/90 fdmF 63/77
c2fdmC1 112 Polyketide cyclase WP_017596466.1 83/90 fdmD 64/76
c2fdmD1 254 Transcriptional regulator WP_116247593.1 58/78 fdmR1 46/64
c2fdmE1 256 Transcriptional regulator WP_081620746.1 67/80 - -
c2fdmF1 144 Unknown WP_017596472.1 78/89 fdmE 59/72
c2fdmG1 179 Transcriptional regulator KPC87453.1 80/84 - -
c2fdmH1 271 Serine hydrolase WP_099880484.1 90/93 - -
c2fdmI1 225 Unknown WP_099880487.1 81/86 - -
c2fdmJ1 394 Transcriptional regulator WP_055497612.1 98/98 - -
c2fdmK1 315 ACP S-malonyltransferase WP_099880491.1 87/92 - -
1 NCBI accession numbers are given.
Mar. Drugs 2020, 18, 284 6 of 12
Figure 4. Map of the genes encoded in BAC 2P5 isolated from a genomic library of S. albus subsp.
chlorinus. Characters from A to K1 indicate the corresponding c2fdm gene described in Table 2.
2.3. Screening for the Mutation Causing Fredericamycin C2 Overproduction and Streptomycin Resistance in
S. albus subsp. chlorinus JR1
Frequently, streptomycin resistance results from a point mutation in the rpsL gene, which codes
for the ribosomal protein S12 [3,4,28–30]. Following genome sequencing of S. albus subsp. chlorinus
JR1, the resulting reads were mapped to the genome of the wild type strain and single nucleotide
mutations were searched in the sequence corresponding to the rpsL gene. No point mutations were
found in this sequence, indicating that the mutation responsible for streptomycin resistance in S. albus
subsp. chlorinus JR1 is located elsewhere in the genome. A total of fifteen point mutations were
detected in the genome of S. albus subsp. chlorinus JR1 (Table S3). A nucleotide insertion was
detected within the coding sequence of the jag gene (SACHL2_00217; position 3714884) that codes for a
single-stranded DNA binding protein. This gene partially overlaps with the adjacent downstream
gene rsmG (SACHL2_00216), indicating their co-transcription in a bicistronic operon. The insertion of
a cytosine nucleotide in the sequence of jag creates a premature stop codon that truncates the protein
translation, also affecting the expression of the co-translating rsmG gene. rsmG codes for a 16S rRNA
methyltransferase, and it has been reported that point-nonsense mutations in its sequence, as well
as the deletion of this gene, lead to increased resistance to streptomycin and enhanced production of
secondary metabolites in different bacterial strains [31,32]. Therefore, we believe that a point mutation
in the jag gene is responsible for high-level streptomycin resistance and upregulation of fredericamycin
C2 (1) biosynthetic gene expression in S. albus subsp. chlorinus JR1 by preventing the translation of the
rsmG gene.
2.4. Biological Activity of Fredericamycin C2
Fredericamycin C2 (1) was tested for antibacterial activity against a Gram-positive (Bacillus subtilis)
and two Gram-negative strains (Escherichia coli and Pseudomonas putida) through disk diffusion test.
The new fredericamycin variant displays a growth inhibition zone against P. putida at a minimal
concentration of 2.5 mg/mL (Figure S4). Fredericamycin C2 (1) shows no inhibitory activity against the
growth of B. subtilis and E. coli.
3. Discussion
Fredericamycin variants constitute a family of aromatic polyketides with significant toxicity
against tumor cells as well as moderate antibiotic and antifungal activity. Here, we present the novel
variant fredericamycin C2 (1), which is overproduced by the strain S. albus subsp. chlorinus JR1,
a spontaneous streptomycin-resistant mutant derived from S. albus subsp. chlorinus NRRL B-24108.
We suggest that a mutation in the jag gene affecting the translation of the adjacent gene rsmG is
responsible for the phenotype of the mutant strain. The frame shift originated by the point insertion
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putatively generates a truncated non-functional Jag protein. In previous studies, deletion of a jag
homologue in Streptococcus pneumoniae led to retarded growth and smaller cell size compared to the
wild type strain, indicating that Jag is likely involved in cell division [33]. However, no association of jag
deletion with increased antibiotic resistance or induction of secondary metabolite production has been
reported before. The point mutation in the jag gene has a polar effect on the overlapping gene rsmG,
preventing its transcription. The enhanced production of fredericamycin C2 (1), as well as the increased
streptomycin resistance observed in S. albus subsp. chlorinus JR1, is most likely derived from the lack
of RsmG function. This is consistent with previous studies where rsmG deletion mutants showed
higher resistance to streptomycin and improved yields of secondary metabolites at a late-growth
phase [34,35]. rsmG encodes a methyltransferase that catalyzes the methylation of 16S rRNA at the
residue G527 (E. coli numbering). This residue, together with C526 and the S12 protein, interacts
with the antibiotic streptomycin [36]. These interactions tend to stabilize the tRNA-mRNA tandem,
which affects the proof-reading process and results in misreading of the genetic code [37]. The absence
of RsmG would generate 16S rRNA molecules non-methylated at residue G527, causing a weaker
binding to streptomycin and making the strain resistant to the antibiotic. Although the mechanism
by which the lack of 16S rRNA methyltransferase may induce the expression of fredericamycin C2
(1) biosynthetic genes in S. albus subsp. chlorinus JR1 remains unknown, we hypothesize that the
mutant experiences an increased protein synthesis rate at a stationary phase, as it has been previously
observed [34,35]. The increased protein synthetic activity leads to expression of both pleiotropic and
pathway-specific regulatory proteins, which eventually enhance the transcription of poorly expressed
secondary metabolite gene clusters. Several attempts to complement the jag and rsmG gene functions
in S. albus subsp. chlorinus JR1 resulted in no recombinant colonies, suggesting the genetic intractability
of the strain (data not shown).
The structure of fredericamycin C2 (1) presented in this paper only differs from that of
fredericamycin C (2) in the polyketide chain length. While fredericamycin C (2) backbone consists of
30 carbon atoms, fredericamycin C2 (1) contains a C26 polyketide chain (Figure 3). Fredericamycin
C (2) biosynthesis begins with the generation of a C6 primer unit (hexadienyl-ACP) by the PKS
initiation module. This starter unit is then transferred to the elongation module, which presumably
catalyzes the sequential decarboxylative condensation of 12 malonyl-CoA molecules, delivering a C30
polyketide chain [22,38]. In the case of fredericamycin C2 (1), we propose that acetyl-CoA functions
as the starter unit, which is elongated by the polyketide synthase through successive incorporation
of malonyl-CoA extender units (Figure 5). This process is most likely catalyzed by the minimal PKS
enzymes encoded by the genes c2fdmB1, c2fdmA1, and c2fdmZ, and the ACP S-malonyltransferase
encoded by c2fdmK1 (Table 2). The resulting C26 polyketide chain is subsequently modified by tailoring
enzymes to eventually yield the product fredericamycin C2 (1) (Figure 5).
Figure 5. Proposed early biosynthesis steps of fredericamycin C2 (1) in S. albus subsp. chlorinus.
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4. Materials and Methods
4.1. General Experimental Procedures
All strains and BACs (bacterial artificial chromosomes) used in this work are listed in Table S4.
Escherichia coli strains were cultured in LB medium [39]. Streptomyces strains were grown on soy flour
mannitol agar (MS agar) [40] for sporulation and conjugation and in liquid tryptic soy broth (TSB;
Sigma-Aldrich, St. Louis, MO, USA). For metabolite expression, liquid DNPM medium (40 g/L dextrin,
7.5 g/L soytone, 5 g/L baking yeast, and 21 g/L MOPS, pH 6.8) or MS agar were used. The antibiotics
kanamycin, apramycin, and nalidixic acid were supplemented when required.
4.2. Isolation and Manipulation of DNA
BAC extraction from a Streptomyces albus subsp. chlorinus-constructed genomic library (Intact
Genomics, St. Louis, MO, USA), DNA manipulation, E. coli transformation, and E. coli/Streptomyces
intergeneric conjugation were performed according to standard protocols [39–41]. Plasmid DNA
was purified with the BACMAX™ DNA purification kit (Lucigen, Middleton, WI, USA). Restriction
endonucleases were used according to manufacturer’s recommendations (New England Biolabs,
Ipswich, MA, USA).
4.3. Strain Generation, Metabolite Extraction, and Analysis
The spontaneous streptomycin-resistant mutant Streptomyces albus subsp. chlorinus JR1 was
obtained after several rounds of selection of streptomycin-resistant colonies growing on MS agar
medium containing increasing concentrations of the antibiotic. MICs of streptomycin were determined
by spreading spores on MS agar plates containing 50, 100, and 200 µg/mL of streptomycin. Metabolites
were extracted from the agar with ethyl acetate acidified with 100% acetic acid up to pH = 2.0, evaporated
and dissolved in methanol. One µL of extract was separated using a Dionex Ultimate 3000 UPLC
(Thermo Fisher Scientific, Waltham, MA, USA), a 10-cm ACQUITY UPLC®BEH C18 column, 1.7 µm
(Waters, Milford, MA, USA), and a linear gradient of 0.1% formic acid solution in acetonitrile against
0.1% formic acid solution in water from 5% to 95% in 18 min at a flow rate of 0.6 mL/min. Samples
were analyzed using an Orbitrap speed mass spectrometer (Thermo Scientific, Waltham, MA, USA).
Data were collected and analyzed with the Thermo Xcalibur software, version 3.0 (Thermo Scientific,
Waltham, MA, USA). The monoisotopic mass was searched in a natural product database.
4.4. Fredericamycin C2 Purification and Quantification
S. albus subsp. chlorinus JR1 was grown for 8 days at 28 ◦C on 50 Petri dishes, each containing
40 mL of DNPM agar. Fredericamycin C2 (1) was extracted from the solid agar using ethyl acetate
acidified with 100% acetic acid up to pH = 2.0. The crude extract was first separated by normal phase
chromatography on a prepacked silica cartridge (Biotage, Uppsala, Sweden) using hexane (solvent A),
chloroform (solvent B), ethyl acetate (solvent C), and methanol (solvent D) (1:1:1:1) as the mobile phase,
in a linear gradient from 0% to 100% of each pair of solvents (A-B, B-C, and C-D). Fractions containing
fredericamycin C2 (1) were detected by LC-MS analysis, pooled together, and further fractionated by
semi-preparative HPLC (Dionex UltiMate 3000, Thermo Fisher Scientific, Waltham, MA, USA) using a
C18 column (Synergi 10 µm, 250 × 10 mm; Phenomenex, Aschaffenburg, Germany) and a 0.1% formic
acid solution in acetonitrile as the mobile phase in a linear gradient. UV spectra were recorded with a
DAD detector at 274 nm and 525 nm. Finally, 0.8 g of fredericamycin C2 (1) was collected in a single
fraction. For quantification, a calibration curve with different fredericamycin C2 (1) concentrations was
constructed (Figure S1).
Fredericamycin C2 (1): Violet, amorphous solid; m/z 521.1077 [M + H]+ (calculated for C27H21O11,
521.1084); UV λmax (MeOH) 195, 248, 274, 345, 490 nm; 1H and 13C-NMR data, Table 1 and
Supplementary Information Figures S2, S5–S10.
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4.5. H-NMR Spectroscopy
NMR data were measured using a Varian VNMR-S600 spectrometer equipped with 3 mm triple
resonance inverse and 3 mm dual broadband probes. Fredericamycin C2 (1) samples were dissolved in
150 µL DMSO-d6/Pyridine-d5 95:5 and measured at 35 ◦C. The residual solvent signal of DMSO was
used as an internal reference.
4.6. Antimicrobial Susceptibility Test
Disk diffusion tests were performed according to [42]. Ten mL of LB soft agar (10 g/L tryptone,
10 g/L NaCl, 5 g/L yeast extract, 7 g/L agar) was inoculated with the strains Escherichia coli GB2005,
Bacillus subtilis ATCC 6633, or Pseudomonas putida KT2440, and poured on LB agar plates. Five paper
disks (Macherey and Nagel, Düren, Germany) were coated with 10, 5, 2.5, 0.5, or 0.25 mg/mL of
fredericamycin C2 (1) solved in methanol and placed onto the solidified soft agar. An additional disk
loaded with methanol was used as a negative control and the antibiotics nalidixic acid, ampicillin,
and chloramphenicol (50µg/mL, respectively) were used as positive controls. The plates were incubated
at 28 ◦C overnight.
4.7. Genome Sequencing, Genome Assembly, and Analysis
S. albus subsp. chlorinus JR1 was sequenced using an Illumina MiSEQ library with 301-bp inserts
(Illumina, San Diego, CA, USA). S. albus subsp. chlorinus JR1 strain genome assembly has a total of
57 contigs, and 5 final scaffolds—7,539,766 bp; 63,833 bp; 4,962 bp; 2,694 bp; and 2,548 bp (assembled
with Newbler version 2, Roche, Basel, Switzerland). Sequencing reads coverage against the S. albus
subsp. chlorinus B-24108 genome (Genbank accession number VJOK00000000) was examined with
Geneious, version 11.0.3 (Biomatters Ltd., Auckland, New Zealand).
4.8. Genome Mining and Bioinformatics Analysis
The genome of S. albus subsp. chlorinus was screened for secondary metabolite biosynthetic gene
clusters using the antiSMASH [43] online tool (https://antismash.secondarymetabolites.org/#!/start).
Analysis of genetic data was performed using the Geneious software, version 11.0.3 (Biomatters Ltd.,
Auckland, New Zealand) [44].
5. Conclusions
Here, we demonstrate the significance of inducing poorly expressed secondary metabolite gene
clusters for the identification of new microbial natural products. A mutation in the genome of the
strain S. albus subsp. chlorinus JR1 obtained by selection of streptomycin-resistant colonies has led
to overproduction and the discovery of the so far undescribed compound fredericamycin C2 (1).
This secondary metabolite expands the structural variability of the fredericamycin family, whose most
prominent member, fredericamycin A, is a potent antitumor drug. Screening for antibiotic-resistant
strains represents a simple and inexpensive approach that has enabled the improvement of secondary
metabolite production in the genetically intractable bacterial strain S. albus subsp. chlorinus.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/18/6/284/s1;
Table S1: Streptomycin MICs for S. albus subsp. chlorinus and S. albus subsp. chlorinus JR1; Table S2: Quantification
of fredericamycin C2; Table S3: Type and location of point mutations in the genome of S. albus subsp. chlorinus
JR1; Table S4: Bacterial strains and BACs used in this work; Figure S1: Calibration curve for fredericamycin
C2 quantification; Figure S2: Important 2D NMR correlations in fredericamycin C2; Figure S3: HPLC-MS
chromatograms of crude extracts from S. albus subsp. chlorinus JR1, S. albus 2P5, and its parental strain S. albus
Del14; Figure S4: Antibacterial evaluation of fredericamycin C2. Figure S5: 1H NMR; Figure S6: 13C NMR;
Figure S7: COSY NMR; Figure S8: HSQC NMR; Figure S9: HMBC NMR; Figure S10: ROESY NMR.
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Tables 
Table S1. Streptomycin MICs for S. albus subsp. chlorinus and S. albus subsp. chlorinus JR1. 
Strain MIC (μg/ml) 
Streptomyces albus subsp. 
chlorinus NRRL B-24108 
< 50 
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Table S2. Quantification of fredericamycin C2 produced by S. albus subsp. chlorinus JR1 and the parental strain 
S. albus subsp. chlorinus NRRL B-24108. 
Strain Peak area (AU)a 
Fredericamycin C2 
concentration (μM)a b 
Streptomyces albus subsp. 
chlorinus JR1 
571,003,904 773.25 (0.1) 
Streptomyces albus subsp. 
chlorinus NRRL B-24108 
10,157,194 14.08 (0.0) 
   aValues indicate the average of three independent measurements 
   bStandard deviation values are shown in parentheses 
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Table S3. Type and location of point mutations in the genome of S. albus subsp. chlorinus JR1. 
Position (bp) Strain Sequence (5’  3’) Type of mutation 
30077 WT 30068-CGGGGGGGGGA-30079 
G insertion 
 mutant 30068-CGGGGGGGGGGA-30080 
636229 WT 363224-CCCTCCTCGA-636233 
C deletion 
 mutant 363224-CCCTCTCGA-636232 
685900 WT 685893-GGCGGGGCGG-685902 
G insertion 
 mutant 685893-GGCGGGGGCGG-685903 
1120949 WT 1120943-GGCCTGGTAC-1120952 
G deletion 
 mutant 1120943-GGCCTGTAC-1120951 
1922752 WT 1922746-CCCGCGAGCG-1922755 
A deletion 
 mutant 1922746-CCCGCGGCG-1922754 
2222897 WT 2222890-GCCCCCCCGG-2222899 
C deletion 
 mutant 2222890-GCCCCCCGG-2222898 
2548236 WT 2548230-CTCCGCGAGC-2548239 
G deletion 
 mutant 2548230-CTCCGCAGC-2548238 
3714884 WT 3714886-CGACCGTGCC-3714877 
C insertion 
 mutant 3714886-CGACCCGTGCC-3714876 
5766153 WT 5766149-GAGTGCGCGC-5766158 
G  C substitution 
 mutant 5766149-GAGTCCGCGC-5766158 
5766154 WT 5766149-GAGTGCGCGC-5766158 
C  G substitution 
 mutant 5766149-GAGTCGGCGC-5766158 
5766161 WT 5766156-CGCCGGCCGG-5766165 
G deletion 
 mutant 5766156-CGCCGCCGG-5766164 
5790341 WT 5790331-CGGGGGGGGGGT-5790342 
G insertion 
 mutant 5790331-CGGGGGGGGGGGT-5790343 
6179245 WT 6179240-GGGCCGCACC-6179249 
G  C substitution 
 mutant 6179240-GGGCCCCACC-6179249 
6213269 WT 6213264-TCCGCCGCTG-6213273 C deletion 
Mar. Drugs 2018, 16, x FOR PEER REVIEW  4 of 16 
 
 mutant 6213264-TCCGCGCTG-6213272 
7015221 WT 7015216-CCTTCCACCC-7015225 
C deletion 
 mutant 7015216-CCTTCACCC-7015224 
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Table S4. Bacterial strains and BACs used in this work. 
Bacterial strain Features Reference/Source 
Streptomyces albus subsp. 
chlorinus NRRL B-24108 
Strain harboring fredericamycin biosynthetic 
gene cluster 
[2] 
Streptomyces albus subsp. 
chlorinus JR1 
Streptomycin-resistant mutant strain 
overproducing fredericamycin C2 
This work 
Streptomyces albus Del14 Heterologous expression host [3] 
Streptomyces albus 2P5 S. albus Del14 strain harboring BAC 2P5  This work 
Escherichia coli ET12567 
pUB307 
Donor strain for intergeneric conjugation [4] 
Escherichia coli DH10β General cloning strain [5] 
BACs   
pSMART AmR; BAC vector Lucigen (USA) 








Figure S1. Calibration curve for fredericamycin C2 quantification. Peak area is represented against 
fredericamycin C2 concentration (μM). The values represent the average of three independent measurements. 
The black line shows the trendline that leads to the equation: 𝒚 = 𝟕. 𝟑𝟖 ∗ 𝟏𝟎𝟓𝒙 − 𝟐. 𝟒𝟗 ∗  𝟏𝟎𝟓. 
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Figure S2. Important 2D NMR correlations in fredericamycin C2. 
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Figure S3. HPLC-MS chromatograms of crude extracts from S. albus subsp. chlorinus JR1, S. albus 2P5, and its 
parental strain S. albus Del14. (A) Extracted ion chromatograms (521.12 ± 0.1 Da). (B) Mass spectrum 
corresponding to tR = 12.7 min from S. albus 2P5 chromatogram displayed in A. 
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Figure S4. Antibacterial evaluation of fredericamycin C2. Disk diffusion tests against Pseudomonas putida, 
Escherichia coli, and Bacillus subtilis are shown. Fredericamycin C2 solved in methanol was loaded onto paper 
disks at concentrations of 10 mg/ml, 5, 2.5, 0.5, and 0.25 mg/ml. NAL: nalidixic acid; Ap: ampicillin; Cm: 
chloramphenicol; (-): negative control (methanol). 
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Figure S5. 1H NMR (600 MHz, DMSO-d6/Pyridine-d5 95:5, 35 °C). 
  
Mar. Drugs 2018, 16, x FOR PEER REVIEW  11 of 16 
 
 
Figure S6. 13C NMR (150 MHz, DMSO-d6/Pyridine-d5 95:5, 35 °C). 
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Figure S7. COSY NMR (600 MHz, DMSO-d6/Pyridine-d5 95:5, 35 °C). 
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Figure S8. HSQC NMR (600 MHz, DMSO-d6/Pyridine-d5 95:5, 35 °C). 
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Figure S9. HMBC NMR (600 MHz, DMSO-d6/Pyridine-d5 95:5, 35 °C). 
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Figure S10. ROESY NMR (600 MHz, DMSO-d6/Pyridine-d5 95:5, 35 °C). 
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Considering the significant amount of approved drugs based on NPs, it is evident 
that these compounds are still a valuable source for the development of new drug 
leads. The application of bioinformatics and genome sequencing techniques in 
bacterial genomes, especially Actinobacteria, has revealed the presence of a vast 
number of NP gene clusters. However, these clusters are very often poorly expressed 
or inactive under standard laboratory cultivation conditions, hindering the detection of 
their corresponding products. In this work, we have applied ribosome engineering, i.e., 
selection of antibiotic-resistant mutants, and heterologous expression of secondary 
metabolite BGCs to induce the expression of silent gene clusters. 
The generation of a high-level streptomycin-resistant mutant derived from S. albus 
subsp. chlorinus led to in situ activation of a gene cluster, resulting in overproduction 
of the new compound fredericamycin C2. It has been previously reported that certain 
spontaneous mutations in the ribosome are responsible for high resistance to 
antibiotics and increased protein synthetic activity during the stationary phase. The 
enhanced protein synthesis can trigger the translation of several global regulatory 
proteins, which subsequently induce the transcription of secondary metabolite gene 
clusters. Ribosome engineering is a simple and cost-effective approach to accelerate 
the discovery of NPs. Nevertheless, one of its drawbacks is the unpredictable effect of 
the ribosomal mutations on the metabolic profile of the mutant strain, since the 
activation of gene expression is not targeted towards any specific gene cluster. 
In contrast, heterologous expression allows the activation of selected clusters, and 
the new products synthesized by the host strain can simply be associated to the 
transferred introduced biosynthetic genes. In an attempt to activate the expression of 
secondary metabolite BGCs, 17 putative gene clusters encoding different classes of 
NPs, including polyketides, non-ribosomal peptides, lanthipeptides, and phenazines, 
were isolated from the genomic library of S. albus subsp. chlorinus and introduced into 
the heterologous hosts S. albus Del14 and S. lividans ΔYA9. As a result, seven clusters 
(40%) were successfully expressed either in S. albus Del14 or in S. lividans ΔYA9. This 
approach led to detection of nybomycin in the extract of one of the clones, enabling 
102 
 
the characterization of its biosynthetic genes, which remained unknown so far. Thus, 
heterologous expression clearly represents a versatile cluster-oriented strategy that 
efficiently unravels the natural structures encoded in bacterial cryptic gene clusters. 
Due to the varied nature of NPs, their successful biosynthesis is influenced by many 
factors, including carbon and nitrogen sources, availability of precursors, and 
expression of their biosynthetic genes, among others. For this reason, the activation of 
silent BGCs is not always achieved either by heterologous expression or by ribosome 
engineering. To overcome these limitations, alternative strategies could be applied. 
For instance, it would be convenient to use several hosts for heterologous expression 
of gene clusters. In the last decade, a panel of diverse heterologous hosts has been 
developed. They harbour different genetic and metabolic backgrounds that might 
provide an optimal environment for the activation of certain BGCs, such as cluster-free 
genomes and absence of competitive metabolic routes, diverse precursors, 
overexpressed global transcription regulators, or absence of transcription repressors, 
among others. Alternatively, the expression of gene clusters can be induced by 
refactoring strategies, which consist in engineering of transcriptional regulatory 
elements of the biosynthetic genes such as promoters, terminators, ribosome binding 
sites, etc. This approach enables the biosynthetic pathways to be uncoupled from their 
native regulation systems. 
In conclusion, the diverse strategies available to induce the expression of cryptic 
secondary metabolite BGCs have successfully untapped novel NPs produced by S. albus 
subsp. chlorinus. Given the structural complexity of NPs of streptomycetes, the 
development of a universal approach that allows the activation of any biosynthetic 
pathway seems very unlikely. Therefore, the establishment of different methods 
remains a crucial starting point to achieve the biosynthesis of the broad array of NPs 
encoded in the genomes of streptomycetes. 
